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A goal in the drug development process, as indicated by the FDA, is to evaluate a 
drug’s ADME profile, as potential drug interactions could exist, leading to adverse drug 
reactions or loss of efficacy. Transport proteins, specifically organic anion transporters 
(OATs) are involved in the absorption, distribution, and elimination of small, negatively 
charged compounds. Although there is an exhaustive list of structurally diverse organic 
anions which interact with OATs, interactions at a molecular level are still shrouded in 
mystery particularly due to the lack of a solved crystal structure. Therefore, in silico 
homology models (hOAT1, 2, 3) were generated using a crystalized protein as template. 
Amino acid contacts predicted to be involved in compound recognition were then altered 
through mutagenesis, followed by accumulation and kinetic studies to evaluate their role 
in compound translocation (hOAT1 and hOAT3). 
Three-dimensional (3-D) homology models were generated for hOAT1, hOAT2 
and hOAT3 utilizing Piriformospora indica high affinity phosphate transporter (PiPT) as 
xiii 
template. The prototypical substrates para-aminohippuric acid (PAH) and estrone sulfate 
(ES) were docked into hOAT1 and hOAT3, respectively. Five amino acid contacts were 
identified after docking within hOAT1-PAH (Arg15, Ile19, Tyr230, Asn439 and Arg466) 
and hOAT3-ES (Tyr342, Phe426, Phe430, Leu431, and Arg454). Initial accumulation 
studies revealed hOAT1 substitutions at positions Arg15Ala, Ile19Ala, Tyr230Ala, 
Asn439Gln, Asn439Ala, and Arg466Ala abolished PAH transport mediated by hOAT1. 
Initial accumulation studies revealed hOAT3 substitutions at positions Tyr342Phe, 
Tyr342Ala, Phe426Ser, Leu431Ala, and Arg454Lys abolished ES transport mediated by 
hOAT3. Kinetic analysis revealed hOAT3 Phe430Ser substitution had a statistically 
significant increase in Km as compared to hOAT3 WT. Additionally, numerous structurally 
divergent compounds were docked within the generated hOAT1, hOAT2, and hOAT3 
models, revealing additional amino acid contacts potentially critical to compound 
recognition and translocation.  
Initial in silico studies revealed amino acid contacts potentially critical in hOAT1, 
hOAT2, and hOAT3 compound recognition. hOAT1 and hOAT3 in vitro studies further 
validated the generated in silico models, as well as emphasized significance in residues 
involved in substrate recognition. Development of these homology models could serve as 











 The proposed studies were the first to use the recently crystallized MFS member, 
PiPT, as a template to generate 3-D homology models of SLC22 family members human 
organic anion transporters (hOAT) 1, 2 and 3. Prior studies on hOAT1 used the glycerol 
3-phosphate transporter (GlpT, SLC37A2) as the protein template [1], however, PiPT 
offers the advantages of belonging to the same transporter superfamily, sharing higher 
sequence identity and similarity with hOATs than GlpT, being crystalized in its occluded 
state, and being even more closely related evolutionarily as it is eukaryotic whereas GlpT 
is prokaryotic. Using these generated in silico homology models for hOAT1 and hOAT3, 
potentially critical amino acid contacts were identified and tested through in vitro efforts. 
Our hypothesis is that substituting amino acid contacts identified will result in changes in 




1B. SPECIFIC AIMS 
 
Specific Aim 1 
 
To identify amino acid residues critical for compound-transporter interaction 
through: 
a. In-silico 3-D homology modeling of OATs using the crystal structure of PiPT 
as the template. 
b. In-silico ligand docking studies using prototypical substrates (PAH for 
hOAT1, ES for hOAT3) to determine the putative binding pocket for each 
OAT. 
c. Identification of amino acids within each transporter’s putative binding 
pocket that mediate interaction with the aforementioned substrates (PAH or 
ES, respectively). 
Specific Aim 2 
 
To mutate amino acids identified as critical in specific aim 1 and observe 
quantitative changes in affinity of OAT substrate recognition by:  
a. Introducing conservative and non-conservative point mutations through use 
of site-directed mutagenesis, thus altering the amino acid residues at 
previous predicted positions. 
b. Establish stably transfected cell lines expressing each OAT mutant. 
c. Perform activity assays to identify mutants as either active or inactive.  
d. Conduct saturation analysis studies on active mutants to determine affinity 
for the associated prototypical substrate (PAH or ES).  
e. Verification of proper membrane targeting of inactive OAT mutants.  
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Specific Aim 3 
 
To dock additional structurally divergent compounds to further characterize 
hOAT1-hOAT3 binding interactions by: 
a. In-silico docking of structurally divergent OAT compounds: PAH, ES, 
penicillin G, α-ketoglutarate (α-KG), acyclovir, salicylate, probenecid, and 
fluorescein, and then identify additional amino acids critical to compound-
transporter interaction.  
b. Comparing amino acids critical to compound-transporter interactions across 




CHAPTER 2 –HUMAN ORGANIC ANION TRANSPORTER 1 (hOAT1) 
 






Organic anion transporters are integral membrane proteins directly involved in 
barrier tissue translocation of small, negatively charged compounds, including drugs, 
xenobiotics, and endogenous molecules. OATs are transport proteins which indirectly 
utilize cellular energy through the stored energy of concentration gradients as the main 
driving force for compound translocation [2]. OATs belong within the solute carrier (SLC) 
22 transporter family, which encompasses organic cation/anion/zwitterion transporters, 
and mediate the cellular entry and exit of anionic and zwitterionic organic molecules. 
Since the initial discovery of human OAT1 (hOAT1) in 1998 [3], extensive functional 
analysis has established primary hOAT1 localization within the basolateral membrane of 
renal proximal tubule cells [3,4]. 
 There is an exhaustive list of structurally diverse organic anions which interact with 
OATs, including drugs classified as diuretics, antihypertensives, antibiotics, antivirals, 
and anticancer agents. Further, various anionic substances intermingle with OATs, 
including endogenous substances such as metabolic intermediates and hormones, in 
addition to environmental toxins and toxicants, such as mycotoxins and pesticides [2]. 
However, interactions at a molecular level are still shrouded in mystery based on the lack 
of structural information available for OATs, particularly lack of a solved crystal structure. 
Thus, alternative methodology has been utilized to predict the 3-D structure of a protein 
sequence based on alignment of a structurally determined crystallized template protein, 
5 
 
also known as comparative modeling [5]. This strategy serves as a viable option for 
hOAT1 until hOAT1’s crystal structure is determined. Thus, it is imperative to identify the 
most suitable template for subsequent analysis. Given the structural elements 
fundamental to OATs, including 12 transmembrane domain (TMD) spanning α-helices, 
intracellular orientation of both N-&-C termini, a large extracellular loop between TMD 1 
& 2, and a large intracellular loop between TMD 6 & 7, crystallized proteins within the 
major facilitator superfamily (MFS) were considered. Previous attempts utilizing MFS 
proteins as a template based on structural characteristics and sequence similarities, 
including the prokaryotic glycerol-3-phosphate transporter (GlpT, SLC37A2), have been 
conducted [1]. While most appropriate at the time, subsequent to these studies additional 
MFS proteins have been successfully crystalized, including the eukaryotic transporter, 
Piriformospora indica phosphate transporter, or PiPT [6]. Using PiPT as a template for 
hOAT1 homology modeling offers the advantages of: 1) belonging to the same transporter 
superfamily, 2) sharing higher sequence identity and similarity with hOAT1 than GlpT, 3) 
being crystalized in its occluded state, and 4) being more closely related evolutionarily as 
it is eukaryotic whereas GlpT is prokaryotic. Given this information, comparative 
homology models based on PiPT’s structure were constructed for hOAT1, followed by 
continued deductions regarding which residues contribute to hOAT1-compound 
recognition, using the prototypical substrate para-aminohippuric acid (PAH). 
 Amino acid residues predicted to be involved in substrate recognition were 
subsequently altered via site-directed mutagenesis in order to evaluate their potential role 
in PAH translocation. Wild-type (WT) and mutated hOAT1 constructs were then 
expressed in Chinese hamster ovary (CHO) cells to allow for their functional analysis. 
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Initial investigation suggested three conservative mutants (Arg15Lys, Ile19Leu, 
Tyr230Phe) exhibited significant changes in PAH accumulation as compared to parental 
CHO cells, albeit with no changes in affinity, as compared to WT hOAT1. All non-
conservative substitutions led to loss of transport activity, indicating some rigidity in these 
positions in regards to PAH recognition. This information provides correlative support of 




2B. MATERIALS AND METHODS 
 
Chemicals and Reagents - [3H] PAH was purchased from PerkinElmer Life and 
Analytical Science (Waltham, MA). Unlabeled PAH, probenecid, and DAPI (4’,6-
diamidino-2-phenylindol) ready-made solution were purchased from Sigma-Aldrich (St. 
Louis, MO). Specific primers for mutation reactions were purchased from Integrated DNA 
Technologies (IDT, Coralville, IA). QuikChange Lightning Site-Directed Mutagenesis Kit 
was purchased from Agilent Technologies (Santa Clara, CA). Lipofectamine transfection 
reagents and Dulbecco’s modified eagle’s/Ham’s F12 medium were purchased from 
Thermo Fisher Scientific (Waltham, MA). QIAprep spin mini and midiprep kits were 
purchased from QIAGEN (Germantown, MD). GoTaq green master mix was purchased 
from Promega (Madison, WI). Abcam plasma membrane protein extraction kit and rabbit 
anti-c-Myc polyclonal antibody were purchased from Abcam (Cambridge, United 
Kingdom). Immuno-Blot assay kit was purchased from Bio-Rad (Hercules, CA). Primary 
actin antibody, alkaline phosphatase (AP) and FITC conjugated secondary antibodies 
were purchased from Santa Cruz Biotechnology (Dallas, TX). 
Molecular Model Building – There were essentially four stages to the 
comparative modeling (Figure 2.1). In summary, the recently solved crystal structure for 
Pirformospora indica high-affinity phosphate transporter (PiPT) was identified as the most 
suitable currently available template molecule and its sequence was downloaded from 
Protein Data Bank (PDB ID: 4J05). The hOAT1 FASTA protein sequence was 
downloaded from the Universal Protein Resource (UniProt, UniProtKB ID: Q4U2R8). 
Looped regions between TMD 1 & 2 and 6 & 7 in the final crystalized form of PiPT were 
excluded based on their inability to resolve these regions [6]. In order to properly align the 
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target (hOAT1) peptide sequence with the known template (PiPT) peptide sequence, 
hOAT1 secondary structures, including potential TMD helices, were predicted using 
PredictProtein v1 [7]. Looped regions between TMD 1 & 2 and 6 & 7 were excluded from 
hOAT1 due to lack of resolved sequence within the PiPT crystal structure. The curated 
sequences were aligned using the multiple sequence alignment software ClustalX v2 [8], 
followed by manual modifications to avoid repetitive regions of non-alignment within 
predicted transmembrane helices, which would negatively impact the model building. The 
final alignment for PiPT-hOAT1 was visualized using ALINE v1.0.025 [9]. Based on this 
alignment, one hundred comparative protein models were generated, using the software 
MODELLER v9.17 [10]. The stereochemical integrity of the generated models was 
evaluated through Discrete Optimized Protein Energy (DOPE) scoring v9.17, [11] and 
Ramachandran plots (PROCHECK v9.17, [12]), both of which ensure bond lengths, 





Figure 2.1 Summarized Steps to Comparative Modeling 
Generalized scheme to initiate the model building procedure utilizing comparative 













































Substrate Docking – An ionized, energy minimized structure for the prototypical 
hOAT1 substrate, PAH, was generated using the computer-aided molecular modeling 
design tool SYBYL-X v2.1 [13].  Proper confirmation and atom type for the sketched in 
silico molecule was evaluated and followed by energy minimization based on Gasteiger-
Huckel charges. Ligand docking studies were initiated using the docking algorithm 
Genetic Optimization for Ligand Docking (GOLD) v5.4 provided from the Cambridge 
Crystallographic Data Centre [14]. Briefly, a GOLD configuration file was generated that 
referenced the previously generated one hundred hOAT1 models as the corresponding 
“receptor” and the in silico PAH molecule as the “ligand”. A spherical region 30Å in 
diameter was designated, which virtually encapsulated the entire transporter. One 
thousand possible combinations were evaluated, and the top combination was selected 
based on GOLD score, DOPE score, and number of clusters. The specific hOAT1-PAH 
combination was then visually inspected using SYBYL-X v2.1, which allows 3-D 
manipulation, thus permitting identification of amino acids deemed potentially critical for 
the formation of the compound-transporter complex. Further validation of these predicted 
critical amino acids was obtained using the empirical molecular modeling system 
Hydropathic Interactions (HINT) [15], which evaluates and scores the binding interactions 
between hOAT1 and PAH.  
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 Mutagenesis – hOAT1 constructs containing single conservative or non-
conservative substitutions at each position hypothesized to be part of the hOAT1-PAH 
binding complex were generated, based upon the physiochemical properties of amino 
acids, amongst other supportive information [16]. Substitutions were introduced into 
pcDNA 3.1 (+) hOAT1 plasmid (Figure 2.2) using the QuikChange Lightning Site-Directed 
Mutagenesis Kit (Agilent Technologies, Santa Clara, CA). Oligonucleotide primers used 
to introduce the mutations were designed online using QuikChange Primer Design 
software (Agilent Technologies, Santa Clara, CA, [17]) and reported in Table 2.1. Cycling 
parameters for QuikChange Mutagenesis Method were as follows: denature at 95°C for 
2 min, 18 cycles of 95°C denature for 20 sec, 60°C annealing for 10 sec, 68°C elongation 
for 30 sec per kb of plasmid length (8kb plasmid, 4 min); with a final elongation at 68°C 
for 5 min. Samples were subsequently incubated with Dpn1 restriction enzyme at 37°C 





Figure 2.2 Plasmid Map of hOAT1 Template  
Full length hOAT1 cDNA sequence was subcloned into pcDNA3.1 (+) plasmid vector 
(Invitrogen, Carlsbad, CA) using BamHI/NotI restriction enzyme sites. Location of hOAT1 
insert is highlighted in yellow. Image generated using SnapGene.  
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Table 2.1 Oligonucleotide primer sequences used for site-directed mutagenesis 
Position Substitution Primer Primer Sequence (5' to 3') 
Arginine 15 
Lysine Forward  GTGGGGGGTGTCGGCAAGTTCCAGCAGATCCAG 
Reverse CTGGATCTGCTGGAACTTGCCGACACCCCCCAC 
Alanine Forward  GGGGGGTGTCGGCGCCTTCCAGCAGATC 
Reverse GATCTGCTGGAAGGCGCCGACACCCCCC 
Isoleucine 19 
Leucine Forward  CCGCTTCCAGCAGTTGCAGGTCACCCTGG 
Reverse CCAGGGTGACCTGCAACTGCTGGAAGCGG 
Alanine Forward  GCCGCTTCCAGCAGGCCCAGGTCACCCTGG 
Reverse CCAGGGTGACCTGGGCCTGCTGGAAGCGGC 
Tyrosine 230 
Phenylalanine Forward  GGGCACCTTGATTGGCTATGTCTTTAGCCTGGGCCAG 
Reverse CTGGCCCAGGCTAAAGACATAGCCAATCAAGGTGCCC 
Alanine Forward  CCTTGATTGGCTATGTCGCCAGCCTGGGCCAGTTCC 
Reverse GGAACTGGCCCAGGCTGGCGACATAGCCAATCAAGG 
Asparagine 439 
Glutamine Forward  GTCTGGCTGCCTCCTTCCAGTGCATCTTCCTGTATAC 
Reverse GTATACAGGAAGATGCACTGGAAGGAGGCAGCCAGAC 
Alanine Forward  TGTCTGGCTGCCTCCTTCGCCTGCATCTTCCTGTATAC 
Reverse GTATACAGGAAGATGCAGGCGAAGGAGGCAGCCAGACA 
Arginine 466 
Lysine Forward  GGCAGCACCATGGCCAAGGTGGGCAGCATCGTG 
Reverse CACGATGCTGCCCACCTTGGCCATGGTGCTGCC 





Position indicates native amino acid; Substitution indicates change (conservative or non-conservative) based on properties 




 Transformation – Dpn1 treated plasmids were incubated with XL10-Gold 
Ultracompetent Cells (Agilent Technologies, Santa Clara, CA). Preheated NZY+ Broth 
was added after heat-pulsing ultracompetent cells at 42°C for 30 sec, followed by 
incubation at 37°C for one hr with constant shaking (225RPM). After incubation, 50, 100, 
and 200μL aliquots of cells were spread onto three separate LB agar plates containing 
100 µg/mL ampicillin, adding a 200μL pool of NZY+ Broth for volumes less than 100μL to 
optimize spreading. Plates were incubated at 37°C for 16 hrs to allow adequate time for 
colony growth. Individual colonies were selected and grown in separate tubes containing 
8mL NZY+ Broth and 100 µg/mL ampicillin, followed by overnight incubation at 37°C with 
constant shaking. 
 Plasmid preparation – Mini or midi-plasmid preparations were performed 
following manufacturer’s protocol [18] (QIAGEN, Germantown, MD). Briefly, pelleted 
bacterial cultures were resuspended, lysed, neutralized, centrifuged at 13,000RPM for 10 
min and supernatants transferred to supplied spin columns. After binding of plasmid DNA, 
columns were thoroughly washed prior to final DNA elution. Plasmid DNA concentration 
was determined using UV-Vis Spectroscopy.  
 Sequencing – Generated hOAT1 mutants were confirmed by DNA sequencing. 
Samples were sent with respective oligonucleotide sequencing primers (Table 2.2) for 
Sanger sequencing (Genewiz, South Plainfield, NJ). Sequencing files provided through 





Table 2.2 Oligonucleotide primers used for hOAT1 DNA sequencing  
Primer Primer Sequence (5' to 3') 
hOAT1 Forward 1 CCCATCTACCATCGTGACTG 
hOAT1 Forward 2 AGTCTGCAGAAGGAGCTGAC 
hOAT1 Reverse 1 CATTGAGCAGGATGCAGATG 





 Cell Culture – CHO control, CHO-hOAT1 WT, and CHO-hOAT1 mutant cell lines 
were maintained at 37°C with 5% CO2 in Dulbecco’s Modified Eagle/Ham’s F-12 Medium 
(DMEM/F12) containing 10% FBS, 1% Penicillin-Streptomycin (Pen-Strep) (Gibco-
Invitrogen, Grand Island, NY) and 0.250 mg/mL G418. Once cells reached 80-90% 
confluency, passaging was performed. Briefly, the media was removed, cells were 
washed with 1x phosphate buffered saline (PBS), followed by cell dissociation using 
0.25% Trypsin-EDTA (Gibco-Invitrogen, Grand Island, NY). Dislodged cells were 
resuspended in medium and passaged to a separate flask containing DMEM/F12, 10% 
FBS, 1% Pen-Strep, and 0.250 mg/mL G418. Cells were sub-cultured every three to four 
days and passages numbered 4 through 20 were used for experiments. 
Transfection – CHO cells were grown in antibiotic-free DMEM/F12 (Gibco-
Invitrogen, Grand Island, NY) with 10% Fetal Bovine Serum (FBS) at 37°C in 5% CO2 
until reaching 60 to 80% confluency. Stable transfections were performed according to 
the Lipofectamine® 2000 Reagent protocol [19]. One day before transfection, 7.0 x 104 
CHO cells were seeded into 12-well tissue culture plates. On the day of transfection, 
Lipofectamine® 2000 (4µL) and OptiMEM medium (96µL) per transfection were 
incubated together for 5 min at room temperature. Plasmid DNA (1µg) was added to 
100µL OptiMEM medium, combined with previous Lipofectamine® 2000/OptiMEM 
mixture, then incubated for 20 min at room temperature. After adding a fresh 1mL of 
medium to each well, the Lipofectamine® 2000/plasmid DNA/OptiMEM mixture (200µL) 
was added to each well and mixed gently. Cells were then incubated at 37°C for 24 to 48 
hrs, followed by multiple weeks of antibiotic selection using 1 mg/mL Geneticin (G418) 
(Gibco-Invitrogen, Grand Island, NY).   
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 Accumulation Assay – The procedure for cell accumulation assay has been 
described previously [20,21]. In summary, 2.5 x 105 cells were seeded with antibiotic-free 
culture medium in 24-well tissue culture plates 48 hrs before the experiment. The culture 
medium was removed and the cells were washed with 500μL transport buffer (TB) for 10 
min. Cells were treated with 400μL TB containing 5µM PAH spiked with radiolabeled PAH 
(0.25 µCi/mL [3H]PAH) in the absence or presence of the inhibitor probenecid (500µM) 
for 10 min. The treatment was removed, and the cells were rinsed three times with ice-
cold TB. Cells were lysed in 200μL 1M NaOH and shaken for two hrs at room temperature. 
Afterward, cells were neutralized with 250μL 1M HCl and 200μL 10mM 4-(2-
hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES). Liquid scintillation was 
conducted using 400μL of samples with 5mL Ecoscint H cocktail (National Diagnostics, 
Atlanta, GA). Samples were normalized by protein content through Bradford protein assay 
using 10μL sample aliquots with 200μL protein assay dye (Bio-Rad Laboratories, CA). 
Screening data were reported as mean ± SD from triplicate samples. 
 Kinetic Analysis Assay – Michaelis-Menten constants (Km) were determined for 
PAH uptake for active hOAT1 mutants through saturation analysis according to our 
previously published protocol [21]. In summary, 2.5 x 105 cells were seeded with 
antibiotic-free culture medium in 24-well tissue culture plates 48 hrs before the 
experiment. Culture medium was removed and the cells were washed with 500μL TB for 
10 min. Cells were treated with 300μL TB containing increasing concentrations of PAH 
(1µM – 200µM; 0.25 µCi/mL [3H]PAH) for one min. The treatment was removed and 
samples processed as described above for the accumulation assay. Data were plotted 
and analyzed by non-linear regression to generate Km estimates (GraphPad v8.3.0). 
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Kinetic data was reported as mean ± SD from triplicate samples. Final Km estimates were 
reported as mean ± SE from a minimum of three separate experiments  
 Verification of Genomic Integration – Cells were suspended in 500μL of lysis 
buffer (1 M Tris (pH 8.0), 5 M NaCl, 0.5 M EDTA, 10% SDS, and 0.4 mg/mL proteinase 
K) and incubated at 55°C overnight while shaking at 200RPM. The following day, genomic 
DNA was extracted using an equal volume of phenol/chloroform/isoamyl alcohol (25:24:1) 
and shaking for 10 min. Samples were centrifuged for 10 min at 15,000RPM in a table-
top microcentrifuge. The upper aqueous phase was collected, mixed with an equal 
amount of isopropyl alcohol, and spun for an additional 15 min to obtain a DNA pellet. 
The pellet was rinsed with 70% ethanol, air-dried, and re-suspended in 200μL TE buffer 
(pH 8.0) containing 10mM Tris and 1mM EDTA. DNA concentration was determined using 
UV-Vis Spectroscopy. Genomic DNA ranging from 150 to 1,000ng, 2x GoTaq Green 
Master Mix (25μL), and 2.5μL primer pair mix (100μM T7: 5’ – 
TAATACGACTCACTATAGGG – 3’; 100μM hOAT1Rev1: 5’ – 
CATTGAGCAGGATGCAGATG – 3’) were added to a final volume of 50μL and run in a 
thermocycler under the following conditions: denature at 95°C for two min, 30 cycles of 
denaturation at 95°C for 30 sec, annealing at 48°C for 30 sec, elongation at 72°C for one 
min. Final elongation proceeded at 72°C for five min, then samples were held at 4°C. 
PCR products were loaded onto a 1% agarose gel for separation using electrophoresis 
at 120V for one hr. Gel was stained in ethidium bromide (EtBr) for 10 min and visualized 
using a ChemiDoc Touch Imaging System (Bio-Rad Laboratories, Hercules, CA).   
20 
 
Western Blotting – COS7 cells expressing hOAT1 c-Myc were generously 
provided by Dr. Guofeng You (Rutgers University, Piscataway, NJ). Total COS7 hOAT1 
cytosolic and plasma membrane fractions were isolated from COS7 hOAT1 c-Myc and 
CHO parent cell lines using a plasma membrane protein extraction kit (Abcam, 
Cambridge, United Kingdom). Briefly, approximately 5 x 107 cells were resuspended in 
homogenization buffer containing proteinase inhibitors and placed in a Dounce 
homogenizer. Cells were homogenized on ice for 10 min. Afterward, cell homogenates 
were spun at 700RPM for 10 min, then the supernatant was collected and transferred. 
The supernatant was spun at 10,000RPM for 30 min. Afterward, the supernatant was 
collected (cytosolic fraction) and the pellet, which contained total membrane protein, was 
resuspended in equal parts upper and lower phase. The resuspended pellet was spun at 
3500RPM, and the upper phase was collected. Five volumes of diH2O was added to the 
upper phase, then spun at 10,000RPM for 10 min. Afterward the pellet, which contained 
plasma membrane protein, was resuspended in radioimmunoprecipitation assay (RIPA) 
buffer containing proteinase inhibitors, then protein concentration was determined 
through a Bradford protein assay. Sodium dodecyl sulfate (SDS) loading buffer (5x) 
containing 2-mercaptoethanol was added to 60 µg protein samples. A Western blot gel 
was prepared consisting of both a 5% stacking gel portion (30% acrylamide, 1M Tris pH 
6.8, 10% SDS, 10% APS, TEMED) and a 10% running gel portion (30% acrylamide, 1.5M 
Tris pH 8.7, 10% SDS, 10% APS, and TEMED). Samples were heated for one hr at 50°C 
then loaded onto the prepared gel submerged in 1x glycine running buffer. 
Electrophoresis was performed in two steps: 90V for 20 min, followed by 150V for one hr. 
Afterward, the gel was washed with diH2O, then rinsed in 1x transfer buffer (glycine, Tris, 
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methanol) and transferred to polyvinylidene difluoride (PVDF) membrane. The transfer 
stage was run at 100mA for one hr with constant stirring. Afterward, the process was 
continued using the Immun-Blot goat anti-rabbit IgG (H + L) AP Assay Kit. The PVDF 
membrane was blocked with 3% gelatin in 1x TBS for one hr with constant shaking. The 
block was removed and the membrane was incubated with rabbit anti c-Myc antibody 
(1:500) overnight at 4°C. The next day, the primary antibody was removed and the 
membrane was incubated with goat anti-rabbit IgG-AP secondary antibody conjugate for 
one hr, followed by three separate, five minute washes with 1xTBST, then a final wash in 
1x TBS. Next, 50uL of both AP Color Reagent A and B containing nitro blue tetrazolium 
chloride/5-bromo-4-chloro-3-indolyl phosphate (NBT/BCIP) was added to AP color 
development buffer, then the solution was added to the PVDF membrane until bands 
were visualized. The NBT/BCIP wash was removed and the membrane was submerged 
in diH2O for 10 min. In addition, the membrane was probed for β-actin (goat anti-actin IgG 
(1:1000), donkey anti-goat IgG-AP (1:5000)) as a loading control. 
hOAT1 Green Fluorescent Protein (GFP) Plasmid: Transfection & 
Microscopy – A hOAT1-GFP fusion protein expression construct was synthesized by 
GenScript (Piscataway, NJ) and confirmed by DNA sequencing. In summary, the coding 
region for hOAT1 was ligated into the pEGFP-C3 plasmid (Invitrogen, Carlsbad, CA) in-
frame with the carboxyl terminal end of GFP using restriction enzymes KpnI/BamHI 
(Figure 2.3). The pEGFP-C3-hOAT1 plasmid was transformed into DH5-α cells, and 
plasmid DNA was extracted through use of a QIAprep miniprep kit. The hOAT1-GFP 
plasmid was transiently transfected into CHO cells (1.0 µg hOAT1-GFP plasmid DNA, 
incubated at 37°C for 24 hr) seeded onto glass coverslips. After 24 hrs, the medium was 
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removed, and the cells were fixed using 4% paraformaldehyde in 1x PBS for 10 min. 
Coverslips were then washed thrice in 1x PBS, followed by 1 µg/mL DAPI solution for two 
min. The DAPI was removed, the coverslips were washed twice in 1x PBS, once in diH2O, 
and mounted onto a microscope slide using DPX Mountant. Fluorescence images were 
taken using an OLYMPUS IX51 microscope containing an X-Cite series 120 fluorescence 
lamp illuminator. Images were collected through use of an OLYMPUS XC30 digital color 





Figure 2.3 Plasmid Map of pEGFP-hOAT1  
Full length hOAT1 sequence was ligated into a pEGFP-C3 plasmid using KpnI/BamHI 
restriction enzyme sites. Location of hOAT1 insert is highlighted in yellow and EGFP 




hOAT1 c-Myc Plasmid: Transfection & Microscopy – CHO cells were 
transfected with 1.0 µg hOAT1 c-Myc plasmid DNA and were incubated at 37°C for 24 
hrs. After 24 hrs, the media was removed, and the cells fixed using 4% paraformaldehyde 
in 1x PBS for 10 min followed by permeabilization in 0.2% Tween 20 for 20 min. 
Coverslips were then washed thrice with 1x PBS, followed by antigen retrieval. Coverslips 
were added to a beaker containing 100°C sodium citrate buffer (pH 6.0) for 20 min, 
followed by cold diH2O for 10 min. Coverslips were then blocked with 1% BSA in 1x PBS 
for 2 hrs at room temperature. Anti c-Myc primary antibody was diluted with 1% BSA in 
TBST (1:100) and the coverslips were incubated overnight at 4°C. Primary antibody was 
removed, the coverslips were washed thrice in 1x PBS, followed by incubation with FITC 
labeled secondary antibody diluted in 1% BSA in TBST (1:100) for one hr at room 
temperature. Secondary antibody was removed and coverslips were processed as 
described above for hOAT1-GFP transfection and microscopy. 
 Cell Sorting – Due to the presence of antibiotic-resistant CHO cells with limited 
hOAT1-mediated transport, cells were sorted using a fluorescent substrate for hOAT1, 
fluorescein, using a BD FACSCanto II system. CHO parent cells (control) were incubated 
with 5µM fluorescein for 15 min then washed thrice in ice-cold TB containing 500µM 
probenecid. The cells were added after their final wash to the instrument to set the 
calibration curve. For the experimental conditions, multiple flasks of CHO hOAT1 WT or 
active mutants (Arg15Lys, Ile19Leu, Tyr230Phe) were separately incubated with 5µM 
fluorescein for 15 min, washed thrice in ice-cold TB containing 500µM probenecid, and 
maintained in the final wash before sorting. Experimental conditions were sterilely sorted 
based on FITC intensity, with the cells exhibiting the strongest fluorescence activity (top 
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5%) collected and transferred to a fresh flask containing DMEM/F12 with 10% FBS, 1% 
Pen Strep, and 0.250 mg/mL G418. 
 Mycoplasma Testing – All cell lines were tested for the presence of mycoplasma 
using a Universal Mycoplasma Detection Kit (ATCC, Manassas, VA). Briefly, adherent 
cells were harvested and resuspended in lysis buffer, heated at 95°C, then spun at 
13,000RPM for five min. Supernatants were collected, followed by the addition of 
Universal PCR mix plus Universal Primers supplied through the kit, with the appropriate 
positive and negative controls. Following the PCR amplification procedure, a 3% agarose 
gel was prepared, and 10μL of PCR products were loaded. The gel was stained using 
EtBr, washed thrice in diH2O, then observed under UV illumination. No instances of 
mycoplasma were detected in any generated CHO hOAT1 expressing cell lines (Figure 
2.4).  
Statistics – Data are plotted as mean ± SD for initial screening assay and 
individual saturation assays. Final Km estimates are reported as mean ± SE. Statistical 
analysis was performed using GraphPad Prism v8.3.0 and R 3.6.0. Equal variance, one-
way ANOVA with post-hoc Dunnett’s multiple comparisons was used to evaluate 
differences compared to a single control where indicated. All differences were considered 


























Figure 2.4 Mycoplasma Testing of Generated CHO cell lines 
Mycoplasma testing of CHO hOAT1 cell lines along with parental CHO cells is shown. 
10μL aliquots were loaded for 100bp DNA ladder, positive control, negative control, and 
CHO cell lines. Mycoplasma was detected for positive control only (Lane 2, 464bp). Lanes 
are as follows: (1) 100bp Ladder, (2) Positive Control, (3) Negative Control, (4) hOAT1 
WT, (5) CHO Parent, (6) hOAT1 Arg15Lys, (7) hOAT1 Arg15Ala, (8) hOAT1 Ile19Leu, (9) 
hOAT1 Ile19Ala, (10) hOAT1 Tyr230Phe, (11) hOAT1 Tyr230Ala, (12) hOAT1 






Comparative Modeling of hOAT1 
 
 An initial Basic Local Alignment Search Tool (BLAST) search of the non-redundant 
protein sequences database was performed using hOAT1 as the target to identify a 
suitable template for homology modeling. Search results indicated the peptide sequence 
of the recently crystallized protein, PiPT, shares 33% sequence similarity and 19% 
sequence identity with hOAT1, signifying PiPT as a more appropriate template than 
previously utilized GlpT (PDB ID: 1PW4), which shares 27% similarity and 16% identity 
with hOAT1. In addition to higher similarity and identity, PiPT offers further advantages 
as a template molecule such as also being a eukaryotic protein, inclusion in the major 
facilitator superfamily (MFS), a 12 TMD structure divided into two domains, and being 
crystallized in the occluded state therein maximizing the interaction within the compound-
transporter complex. Thus, PiPT was selected to serve as the template. 
Both PiPT and hOAT1 are predicted to have large sequence loops between TMDs 
1 & 2 and 6 & 7. Due to their flexibility, these loops are not resolved in the PiPT crystal 
structure, thus there are no corresponding residues to model. Therefore, before alignment 
of hOAT1 and PiPT peptide sequences, the hOAT1 sequence (UniProtKB ID: Q4U2R8) 
was truncated from Ile44 – Ser129 (between TMDs 1 & 2) and Ser277 – Leu329 (between 
TMDs 6 & 7). The final sequence alignment is shown in Figure 2.5, showing the TMDs 
for PiPT (white) and hOAT1 (yellow) as well as exact positioned identities (white letters). 
This alignment file was fed into MODELLER, generating 100 separate in silico homology 
models for hOAT1.  
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Next, docking studies were conducted using GOLD v5.4 where the energy 
minimized PAH structure was docked into each model separately, ten times, generating 
a total of 1,000 different combinations between hOAT1 and PAH. To determine the top 
hOAT1-PAH combination, models were ranked through evaluation of their DOPE and 
GOLD scores as well as cluster analysis. As shown in Table 2.3, the top hOAT1 model 
was number 4 with PAH pose number 45. Overall, this combination had the highest GOLD 
score (65.30), the second-highest DOPE score (-45539.37), and the same number of 
clusters (1) as the top four GOLD ranked solutions reported. To further evaluate hOAT1 
model 4, a Ramachandran plot was generated using the program PROCHECK v9.17 
allowing visualization of all bond angles. Favorable bond angles appear in the red and 
yellow regions whereas disallowed angles are located in the white areas (Figure 2.6).  
Only three residues, Ser160, Ala331, and Tyr334, were identified as forming disallowed 
bond angles in this model. These residues are positioned on the outskirts of the in silico 
model, i.e. well outside the putative PAH binding domain, and thus likely exert no direct 
influence on the hOAT1-PAH binding complex in this model. It was also of interest to 
visualize all top PAH solutions docked, to better validate the top model chosen (Figure 
2.7). The top PAH pose is displayed as a space-filling molecule to distinguish from all 
other PAH molecules docked. This molecule is positioned centrally within hOAT1, 
clustered amongst numerous additional PAH molecules that were separately docked. 
This provides further validation that the top PAH pose (45) is an appropriate 
representation of the GOLD docking results generated, in addition to providing further 
support to a clear single, centralized binding region. Thus, hOAT1 model 4 was selected 
as the best representation of hOAT1 in the occluded state with PAH (Figure 2.8). As 
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shown, the generated hOAT1 model has 12 predicted TMDs with intracellular amino and 
carboxyl termini, with multiple TMDs contributing to the binding pocket. PAH is 






Figure 2.5 Peptide Sequence Alignment Between PiPT and hOAT1 
Final peptide sequence alignment between PiPT (top) and hOAT1 (bottom). 
Transmembrane domain (TMD) regions for PiPT (white) documented and confirmed 
through crystallization of the protein. TMD regions for hOAT1 were initially predicted 
through PredictProtein v1 software, then regions were determined (yellow) upon final 
model generation.  White letters indicate conserved amino acid residues between target 
and template. Image generated using the program ALINE v1.0.025. 
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Table 2.3 Summary of evaluative parameters and ranking for the top 15 hOAT1 
models 














1 65.30 4 45 -45539.37 1 
2 58.62 88 28 -45958.39 1 
3 57.63 67 38 -45221.56 1 
4 57.53 32 48 -45102.04 1 
5 56.94 82 4 -44844.93 4 
6 56.74 9 12 -45426.21 2 
7 56.07 76 2 -45471.81 5 
8 55.86 68 15 -45063.06 2 
9 54.90 93 11 -44951.75 3 
10 54.74 83 31 -45153.58 1 
11 54.50 86 14 -45219.59 2 
12 54.47 10 55 -45286.07 1 
13 53.86 29 1 -45127.43 7 
14 53.76 51 17 -45499.86 2 






Figure 2.6 Ramachandran Plot of Top hOAT1 Homology Model 
Axes indicate degree value of rotatable bonds present between neighboring amino acid 
residues with specific model generated. High percentage of amino acid residues were 
reported within favorable regions (99%), with remaining residues (SER160, TYR334, 




Figure 2.7 Summary of All PAH Docked Poses within hOAT1 
The summary of all PAH locations upon successful GOLD docking studies. The PAH 
locations for all modeling studies are indicated as line molecules. The top PAH location 
(pose 45) is shown as a space-filling molecule. The multicolored helices represent the 12 
TMD regions for hOAT1. Image file generated using PyMOL 1.8. 
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Using PyMOL v1.8, further analysis was focused within the suggested binding 
pocket to determine which amino acid contacts within the transporter are critical to PAH 
recognition (Figure 2.9 A & B). Five amino acids with potential PAH interactions were 
identified, specifically Arg15, Ile19, Tyr230, Asn439 and Arg466. The nature of the 
proposed interactions between each residue and PAH are summarized in Table 2.4.  A 
hydrogen bond interaction was predicted for amino acids Arg15, Asn439 and Arg466. In 
addition, Ile19 was proposed to exhibit a hydrophobic interaction, and an edge-face 
aromatic interaction was identified for Tyr230. To directly examine these predicted amino 
acid – PAH interactions, conservative and non-conservative substitutions were 






Figure 2.8 Three-Dimensional in silico hOAT1-PAH Model 
Three-dimensional side view (left) and top view (right) of the generated hOAT1-PAH 
binding complex. The multicolored helices represent the 12 TMD regions for hOAT1 and 
are numbered in the top view.  A space filling representation of PAH is shown with putative 






Figure 2.9 A & B Different Rotational Views of the hOAT1-PAH Binding Complex 
The five amino acids predicted to be important for PAH binding and transport are 














Table 2.4 Summary of putative PAH-hOAT1 complex forming amino acids, the 
predicted nature of each interaction and generated conservative and non-
conservative hOAT1 mutations 
TMD Amino Acid Interaction Conservative 
Non-
conservative 
1 Arg15 Hydrogen Bond Lys Ala 
1 Ile19 Hydrophobic  Leu Ala 
5 Tyr230 Edge-Face Aromatic Phe Ala 
10 Asn439 Hydrogen Bond Gln Ala 
11 Arg466 Salt Bridge featuring Bidentate Hydrogen Bond Lys Ala 
 
Interactions proposed are based on each amino acid’s orientation with the docked 
substrate. Conservative and non-conservative substitutions were based on 




In Vitro Testing 
 
 The identity of all hOAT1 mutant constructs was confirmed by DNA sequencing 
prior to functional examination. Representative chromatograms for both a hOAT1 
conservative (Arg15Lys) and non-conservative (Arg15Ala) mutation are shown. In Figure 
2.10 panel A the WT ‘CGC’ codon for arginine is clearly observed, while in panel B the 
codon has been mutated to ‘AAG’ which codes for lysine. Similarly, in Figure 2.11 it can 
be seen that the WT arginine codon has been altered to ‘GCC’ which codes for alanine. 
For undetermined reasons, the conservative substitution Arg466Lys could not be 
generated. Several attempts were made, however in each instance the mutagenesis 
primer sequence appeared in tandem thus significantly altering the hOAT1 coding 
sequence in the final construct. Further work involving this conservative substitution was 







Figure 2.10 Representative Chromatogram for DNA Sequencing Confirmation of 
hOAT1 Conservative Mutants. 
The chromatogram for hOAT1 WT (A) and hOAT1 Arg15Lys (B) sequence. The triplet 
codon region highlighted shows position of mutation. The three letter amino acid codon 








Figure 2.11 Representative Chromatogram for DNA Sequencing Confirmation of 
hOAT1 Non-conservative Mutants. 
The chromatogram for hOAT1 WT (A) and hOAT1 Arg15Ala (B) sequence. The triplet 
codon region highlighted shows position of mutation. The three letter amino acid codon 





After establishing stably-expressing WT and mutated hOAT1 cell lines, initial 
accumulation assays were performed to quantify PAH transport activity. Cells were 
exposed to PAH (5µM) in the absence or presence of the inhibitor probenecid (Figure 
2.12). As shown, hOAT1 WT cells showed marked accumulation of PAH (~55 fold) 
compared to CHO parental cells (275.6 ± 21.8 vs. 5.4 ± 1.0 pmol/mg protein/10 min, 
respectively). The known hOAT1 inhibitor probenecid (500µM) showed virtually complete 
inhibition of hOAT1-mediated PAH uptake, as accumulation was comparable between 
probenecid exposed hOAT1 WT cells and CHO parental cells (6.0 ± 0.5 vs. 5.0 ± 0.2 
pmol/mg protein/10 min, respectively). Cell accumulation assay demonstrated that 
conservative substitutions Arg15Lys (230.4 ± 22.0 pmol/mg protein/10 min), Ile19Leu 
(407.5 ± 29.1 pmol/mg protein/10 min), and Tyr230Phe (252.9 ± 36.3 pmol/mg protein/10 
min) all retained PAH transport activity as compared to CHO parental cells. One 
conservative (Asn439Gln) and all non-conservative (Arg15Ala, Ile19Ala, Tyr230Ala, 
Asn439Ala, Arg466Ala) substitutions abolished PAH transport mediated by hOAT1. To 
determine if hOAT1 mutant cell lines were considered transport active or inactive, equal 
variance ANOVA with Dunnett’s multiple comparisons between hOAT1 mutant cell lines 
and CHO parental background cells was performed. Three cell lines (Arg15Lys, Ile19Leu, 
Tyr230Phe) were found to be statistically different from CHO parent (p < 0.0001), 
indicating these three cell lines are transport active mutants. The remaining cell lines 
(Arg15Ala, Ile19Ala, Tyr230Ala, Asn439Gln, Asn439Ala, Arg466Ala) were not statistically 





Figure 2.12 Initial PAH Transport Activity Assay Assessment of hOAT1 Mutants 
Initial accumulation assay with 5µM PAH in the absence (black) and presence (white) of 
500µM probenecid.  Y-axis labels indicate the hOAT1 protein expressed in the stable cell 
line tested including hOAT1 WT (hOAT1), parental background (CHO Parent), and the 
generated conservative and non-conservative hOAT1 mutants. Accumulation was 
performed over a 10 min period and corrected by protein content. Values reported as 
mean ± SD of triplicate samples. Significance indicated by *p < 0.0001 as determined by 




For the active hOAT1 mutant cell lines, further kinetic analysis was conducted to 
determine if mutant cells exhibited changes in PAH affinity (Km) as compared to hOAT1 
WT. Cells were exposed to increasing concentrations of PAH (1µM – 200µM) for one 
minute and representative plots are shown in Figure 2.13. All constructs exhibited 
saturable transport activity and final Km estimates are summarized in Table 2.5. As shown 
in Table 2.5, the hOAT1 mutants Arg15Lys and Tyr230Phe had reduced Km estimates for 
PAH (16.1 ± 1.9 and 20.1 ± 3.5 µM, respectively), but the reductions were not significant 
at the p < 0.05 level. The Ile19Leu mutant (26.8 ± 3.6 µM) had virtually an unchanged Km 




A; CHO hOAT1 WT B; CHO hOAT1 Arg15Lys 
C; CHO hOAT1 Ile19Leu D; CHO hOAT1 Tyr230Phe 
 
Figure 2.13 Saturation Analysis Conducted for hOAT1 WT and Active Mutants 
One minute uptake of increasing concentrations of PAH (1µM – 200µM) spiked with 
[3H]PAH (0.25 µCi/mL) in (A) CHO hOAT1 WT, (B) CHO hOAT1 Arg15Lys, (C) CHO 
hOAT1 Ile19Leu, and (D) CHO hOAT1 Tyr230Phe cell lines. Data were corrected for 
background measured in CHO Parent control cells. Km values were determined using 
Michaelis-Menten nonlinear regression using GraphPad Prism. Experiments within each 
cell line were repeated a minimum of three times in triplicate with final Km estimates 
reported as mean ± SE. Each panel consists of a representative curve, with values plotted 




Table 2.5 Estimated Km for hOAT1 WT and hOAT1 active mutants 
Transporter Km (µM) N 
hOAT1 WT 26.1 ± 2.1 3 
hOAT1 Arg15Lys 16.1 ± 1.9 4 
hOAT1 Ile19Leu 26.8 ± 3.6 3 
hOAT1 Tyr230Phe 20.1 ± 3.5 5 
 
Values are reported as mean ± SE. 
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Genomic Integration of hOAT1 Mutant Constructs 
To confirm successful transfections of transport inactive cell lines, genomic DNA 
from each transfected cell line was isolated and used as template for PCR. Primers 
consisted of the plasmid sequence specific T7 primer and the hOAT1 reverse 1 
sequencing primer (Table 2.2) which should yield full length (~2,000bp) amplification of 
the hOAT1 insert. As shown in Figure 2.14, the expected product band was detected in 
every instance, except for non-transfected CHO Parent negative control (lane 2), 
























Figure 2.14 Confirmation of Construct Integration into Genomic DNA 
Confirmation of successful genomic integration of mutant hOAT1 constructs. Lanes are 
as follows: (1) 1kb Ladder, (2) CHO Parent, (3) hOAT1 WT, (4) hOAT1 Arg15Lys, (5) 
hOAT1 Arg15Ala, (6) hOAT1 Ile19Leu, (7) hOAT1 Ile19Ala, (8) hOAT1 Tyr230Phe, (9) 





Membrane Targeting of Inactive Mutants 
 
Upon completion of the initial accumulation assay with PAH, six hOAT1 mutant 
cell lines (Arg15Ala, Ile19Ala, Tyr230Ala, Asn439Gln, Asn439Ala, Arg466Ala) failed to 
demonstrate PAH transport when compared to CHO parent. To initially investigate the 
translation and membrane targeting for hOAT1, full length hOAT1 cDNA was ligated into 
vector pEGFP-C3, forming the hOAT1-GFP plasmid which expresses a GFP-hOAT1 
fusion protein. CHO cells transiently transfected with hOAT1-GFP plasmid were imaged 
and representative micrographs are shown in Figure 2.15. Cells expressing hOAT1-GFP 
showed strong fluorescence, with lack of signal detected in the nucleus (Panels C & D). 
However, given the high cytoplasmic fluorescence, membrane specific targeting of the 
WT hOAT1 fusion protein could not be conclusively demonstrated or ruled out, thus this 
technique was not explored further with inactive mutants. Cells were stained and imaged 
for DAPI signal (Panels A & B) to ensure cell monolayer was confluent with attached cells. 

























Figure 2.15 Expression Pattern of hOAT1-GFP 
CHO cells transfected with pEGFP-C3/hOAT1 were fixed and mounted at 24 hrs post-
transfection then viewed by fluorescence microscopy: (A) DAPI, 20x (B) DAPI, 40x (C) 




 As an alternative method for evaluating membrane targeting of non-functional 
hOAT1 mutants, use of an artificially c-Myc tagged hOAT1 construct was explored. CHO 
cells transiently transfected with hOAT1 c-Myc plasmid were imaged and representative 
micrographs are shown in Figure 2.16. The expression pattern of hOAT1 WT c-Myc 
showed strong nuclear fluorescence, with no detectable signal at the plasma membrane 
(Panel C). In addition, cells were stained for DAPI, which when merged with FITC signal, 
showed strong overlapping signal (Figure 2.16 Panel D), thus indicating endogenous c-
Myc protein in the nucleus. Control transfections (lipofectamine only) showed a similar 
fluorescent pattern as compared to cells expressing hOAT1 WT c-Myc (data not shown). 
Since the COS7 hOAT1 c-Myc cells do exhibit transport activity [23], some of the tagged 
transporter clearly traffics to the cell surface, therefore, in the absence of observable 

























Figure 2.16 Immunohistochemistry of hOAT1 c-Myc Expressing Cells  
CHO cells transfected with pcDNA3.1 hOAT1 c-Myc were fixed, permeabilized, 
subjected to heat antigen retrieval and mounted at 24 hrs post transfection, then viewed 
by fluorescence microscopy: (A) DAPI, 20x (B) DAPI, 40x (C) FITC, 40x and (D) DAPI & 




 Finally, in addition to immunohistochemistry, Western blotting was performed on 
isolated cytoplasmic and plasma membrane fractions from COS7 cells expressing hOAT1 
WT c-Myc using the c-Myc antibody. Protein bands were observed at the expected 
position of full length endogenous c-Myc protein (~48kD), however no detectable signal 
was observed in the hOAT1 WT c-Myc membrane fraction (~66kD, Figure 2.17 A). The 
membrane was additionally blocked then probed for β-actin as a loading control. 
Detection for β-actin was consistently observed (~43kD) in all lanes (Figure 2.17 B).  
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Figure 2.17 Immunoblotting of hOAT1 c-Myc Expressing Cells 
Western blot images of cytosolic and membrane fractions from control and hOAT1 c-
Myc expressing cells after probing for c-Myc (A) followed by β actin (B). Lanes are as 
follows: (1, 5, 6, 10) 5µL Ladder, (2, 7) COS7 hOAT1 c-Myc Membrane (60 µg), (3, 8) 




2D. DISCUSSION  
 
Although it has been over two decades since the first discovery of OATs, information 
is still lacking regarding the structural components that impact compound recognition at 
the molecular level. Thus far, attempts to crystallize SLC22 family members have been 
unsuccessful, thus, homology modeling has been employed. Previous work has been 
conducted using bacterial GlpT as template to develop a model for hOAT1 [1]. Recently, 
however, a protein within the MFS, PiPT, was crystallized and represents a more suitable 
template for hOAT1 modeling studies. PiPT belongs to the same transporter superfamily, 
shares higher protein sequence identity (19%) and similarity (33%) with hOAT1 than GlpT 
(16% and 27%, respectively), and is more closely related evolutionarily as it is a 
eukaryotic protein whereas GlpT is prokaryotic. In addition, the International Transporter 
Consortium has designated PiPT as the appropriate template for SLC22 transporters [24]. 
Finally, in a June 2019 article regarding current advances in studying clinically relevant 
transporters of the SLC family, PiPT was also identified as the preferred template for 
structure-based modeling [25]. Therefore, in this work molecular modeling studies were 
conducted using PiPT as template. 
One hundred models were constructed to represent the proposed alignment between 
PiPT and hOAT1, which aids in distinguishing small bond angles and torsional rotations 
over the course of the model building procedure. Of the potential 1,000 combinations 
generated, the top 15 results are reported in Table 2.3. The best combinations between 
hOAT1 and PAH are listed in descending order of “GOLD Rank”. Choosing which model 
and pose combination to continue with was based on GOLD scores, DOPE scores, and 
number of clusters. DOPE scores aid through increasing the accuracy of the protein 
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structure assessment [11,26]. GOLD scoring takes into account hydrogen bond energy, 
protein-ligand van der Waals energy, ligand internal van der Waals energy, and ligand 
torsional strain energy to predict appropriate and feasible ligand binding positions [14]. 
Based upon these criteria, hOAT1 model 4 was selected (out of 100), and the best pose 
of PAH within this model was number 45. Further evaluation of model 4 was conducted 
via Ramachandran plot analysis. Such analysis provides an additional detailed check on 
the stereochemistry of the protein structure in the proposed model (Figure 2.6). This plot 
provides assessment of the overall quality of the structure and also highlights regions 
which may require further investigation [12]. As indicated, in model 4 99% of the residues 
exist in “allowable” or “favorable” conformations and only three residues, Ser160, Ala331, 
and Tyr334, were identified as having inappropriate bond angles between neighboring 
amino acids. Further visual inspection of the model confirmed these three residues reside 
towards the outer surface of the protein, a significant distance from the putative PAH 
binding domain identified herein. Therefore, these residues were viewed as likely being 
non-influential to the final hOAT1-PAH result. Finally, when all 1,000 PAH docking results 
were observed as a group it was clear a single, centralized binding region emerged and 
the top PAH pose (i.e pose 45, displayed as a space-filling molecule to distinguish from 
all other PAH molecules docked) is positioned within this centrally located region within 
hOAT1 (Figure 2.7). Thus, model 4 was selected (Figure 2.8).  
Side (left) and top (right) views of the generated hOAT1 model illustrate the 12 TMD 
regions, along with the proposed binding pocket PAH occupies (indicated by the grey 
space-filling cluster). Initial investigation revealed amino acid residues predicted to 
interact with PAH, and they are labeled and visualized in Figure 2.9 A & B. Three residues, 
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Arg15, Asn439, and Arg466, have the potential for hydrogen bonding (Table 2.4). The 
guanidinium groups present within the arginine amino acids appear to align with the 
electronegative group of the carboxylic acid within PAH. For asparagine, the carboxylic 
acid group acts as an electronegative group to the positive amine group within PAH. 
Isoleucine 19 may exhibit what is known as a hydrophobic interaction: the nonpolar 
properties of the isoleucine group appear to associate with the benzene ring within PAH, 
and thus form in a hydrophobic pocket. Finally, the aromatic ring of Tyr230 appears to 
interact with the aromatic ring of PAH, leading to an edge-face aromatic interaction. 
Based on the structure of a benzene ring, electronegativity is subject to moving freely 
above and below the ring, leading to an overall positive charge on the benzene edge. 
Therefore, it is proposed that the electronegativity below the tyrosine ring interacts with 
the positivity on the edge of the ring within PAH (Figure 2.9 B). 
Previous hOAT1 modeling based upon the GlpT template preliminarily identified 
positions Tyr230, Lys431 and Phe438 as important for PAH/hOAT1 interactions [1]. We 
also identified Tyr230 as possibly contributing to PAH binding (as discussed above). 
However, unlike the previous study, Lys431 and Phe438 were not identified as possible 
interacting residues. In the current PiPT based hOAT1 model, Lys431 is located well 
outside of the putative binding pocket and poorly positioned to contribute to PAH 
interactions in this conformation and thus was not considered. Phe438, on the other hand, 
was identified within the confines of the hOAT1-PAH binding pocket. Upon further HINT 
analysis, however, this residue was also deemed non-influential in PAH recognition. 
There were several differences in the modeling approaches that likely explain these 
discrepancies, (1) different template molecules were used (GlpT vs PiPT), (2) the GlpT 
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structure did not have substrate included whereas PiPT was crystallized in the occluded 
state and (3) the previous investigation did not actively dock PAH within the proposed 
hOAT1 model (thus limiting visual conformation that specific residues are located within 
the binding pocket), but rather identified favorable active site positions based on size, 
shape and burial extent of protein void volumes using Putative Active Sites with Spheres 
(PASS) software [1]. 
In order to test whether the residues identified in the current study truly impact hOAT1-
PAH interactions, conservative and non-conservative amino acid substitutions were 
introduced (Table 2.4). Initial transport activity assays confirmed three hOAT1 mutants, 
Arg15Lys, Ile19Leu and Tyr230Phe, mediated inhibitor-sensitive PAH uptake that was 
significantly (p < 0.0001) greater than CHO parental background (Figure 2.12). All other 
mutants were determined to be transport inactive, as PAH accumulation was not 
significantly different from background. Every non-conservative substitution led to 
inactivity. This was likely due to the drastic change of the initial amino acid to alanine, a 
residue devoid of a physiochemical influencing functional group, thus limiting the potential 
interaction with the substrate, PAH. One conservative substitution, Asn439Gln, was also 
inactive, potentially indicating the importance of asparagine at this position; e.g. the 
hydrogen bond between it and PAH is crucial for PAH translocation and altering this 
residue disrupts substrate recognition. 
 While the three hOAT1 conservative mutants still recognized and transported PAH 
to some degree, it was unknown whether mutation led to altered affinity for PAH. 
Therefore, these mutants were subjected to saturation (kinetic) analysis in order to 
estimate the Km for PAH and directly compare this to the hOAT1 WT Km (Figure 2.13). 
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The hOAT1 WT Km for PAH determined in these studies was 26.1 ± 2.1µM, which is in 
good agreement with the previous literature [27,28]. Estimated Km values for both 
Arg15Lys and Tyr230Phe trended lower (16.1 ± 1.9 and 20.1 ± 3.5µM, respectively), while 
Ile19Leu had a similar Km value of 26.8 ± 3.6µM (Figure 2.13 and Table 2.5). Regardless, 
no active mutant Km estimates were found to be statistically different from hOAT1 WT (p 
> 0.05). Further studies are required to determine if multiple substitutions within the same 
molecule (i.e., double or triple mutants) will result in notable changes in transporter 
affinity. 
 Several explanations exist for the lack of PAH transport activity by Arg15Ala, 
Ile19Ala, Tyr230Ala, Asn439Gln, Asn439Ala and Arg466Ala; 1) failed integration of full 
length hOAT1 cDNA into the genomic DNA during transfection, 2) substitution of the 
native amino acid truly impacted substrate recognition based on a critical interaction with 
PAH, or 3) substitution disrupted proper folding and/or targeting of the protein to the 
plasma membrane following translation. Genomic integration of intact cDNA for all hOAT1 
constructs was confirmed by PCR (Figure 2.14), demonstrating at the very least 
successful genomic integration. In order to examine proper targeting of the inactive 
hOAT1 mutants to the membrane, numerous techniques were attempted. The first 
method tried was based on previous successes utilizing transporter-GFP fusion proteins 
to directly visualize plasma membrane targeting of rat Oat1 and rat Oct2 [29,30]. A similar 
approach was designed and performed, as hOAT1 was fused to the C-terminus of GFP 
to evaluate membrane targeting of inactive hOAT1 mutants (Figure 2.15). While 
fluorescent signal was clearly excluded from the nucleus, indicating expression of the 
intact hOAT1 - GFP fusion construct, excessive cytoplasmic signal prevented conclusive 
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examination at the cell surface. A second technique involved introducing a c-Myc epitope 
tag at the carboxyl terminus of hOAT1 [31]. COS7 cells expressing the hOAT1-c-Myc 
tagged protein were subjected to immunohistochemistry utilizing a commercial c-Myc 
antibody (Figure 2.16). The observed expression pattern showed abundant endogenous 
c-Myc localized in the nucleus (merged images show complete overlap of DAPI and FITC 
signals within the nucleus (Figure 2.16 D)) however, no discernable signal was associated 
with the cell surface. Control transfections indicated a similar pattern: strong FITC and 
DAPI signal within the nucleus (data not shown). Thus, despite remaining transport active, 
there may be insufficient hOAT1 c-Myc protein at the cell surface to visualize with this 
technique. Finally, Western blotting was conducted on plasma membranes isolated from 
hOAT1 c-Myc expressing COS7 cells. Again, however, the anti c-Myc antibody failed to 
detect hOAT1-c-Myc (~66kD), but did successfully detect native c-Myc (~48kD) for both 
COS7 hOAT1 c-Myc and CHO background fractions (Figure 2.17 A). The blot was 
additionally probed for β-actin as a control to ensure sample integrity, leading to a 
detectable band (~43kD) in all lanes (Figure 2.17 B). Human OAT1 expression levels 
below assay limits of detection also could be the issue here. The detection kit utilized is 
able to detect “sub-nanogram” levels of protein. However, targeted proteomics studies in 
both rat and mouse kidney have reported 10.6 fmol/µg protein and 12.7 fmol/µg protein 
[32,33], in proximal tubule basolateral membrane or renal cortex fractions, respectively. 
Therefore, if hOAT1 c-Myc expression level in COS7 cells is equivalent to native 
expression levels, 60 µg of membrane might have ~636 fmol of hOAT1 c-Myc and a one 
hundred fold overexpression would result in ~63.6 pmol of hOAT1 c-Myc. Thus, 
potentially indicating these standard detection techniques lack sufficient sensitivity to 
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detect target and that a targeted proteomics approach is required for 
detection/quantification. 
 In summary, a novel in silico homology model for hOAT1 based on the solved 
structure of PiPT was successfully constructed and validated. Upon successful docking 
of the prototypical substrate, PAH, into the generated hOAT1 model, residues Arg15, 
Ile19, Tyr230, Asn439 and Arg466 (involving four separate TMDs) were identified as 
potentially critical to PAH recognition. Regardless of position, non-conservative 
substitution to alanine led to complete loss of transport activity. Conservative substitutions 
at positions 15, 19, and 230 did not significantly alter transport affinity for PAH, 
demonstrating a degree of tolerance at these positions in hOAT1 without loss of 
transporter function. The loss of transport activity for the conservative substitution at 
position 439 suggests that there is less flexibility at this position or that asparagine is 
required at this position for effective PAH transport. Future work will be focused on 
confirming non-functional hOAT1 mutants in regards to membrane targeting to further 
strengthen our conclusions. Ideally, such models will serve as invaluable tools supporting 
future targeted rational drug design strategies, the prediction of potential transporter-
mediated drug interactions, and in silico modeling and prediction of drug pharmacokinetic 
profiles of new chemical entities and investigational drug products. 
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CHAPTER 3 – HUMAN ORGANIC ANION TRANSPORTER 3 (hOAT3) 
 




Organic anion transporters are integral membrane proteins involved in the 
translocation of small, negatively charged compounds, including but not limited to drugs, 
xenobiotics, and endogenous molecules. Within the SLC transporter family lies another 
specific anion transporter: human organic anion transporter 3 (hOAT3), which was first 
characterized in human renal proximal tubules in 1999 [4,34]. 
 Pre-clinical studies involving drug transport protein function are essential, as 
transporters have clinically relevant effects on the pharmacokinetics and 
pharmacodynamics of drugs through impacting their absorption, distribution, and 
elimination [35]. Further, there are increasing examples in the literature where these 
transporter proteins are the site of deleterious drug-drug interactions in the clinic [36–38]. 
In fact, such information is now recognized as being so vital to the drug development and 
approval process that the Center for Drug Evaluation and Research (CDER) within the 
United States Food and Drug Administration (FDA) has outlined a guidance for the 
pharmaceutical industry in regards to in vitro metabolism and transporter mediated drug-
drug interaction studies. Within this FDA guidance, OAT1 and OAT3 are specifically 
identified as renal transporters possibly requiring in vitro studies to determine whether an 
investigational drug is a substrate for either transporter, and to evaluate the potential for 
significant impact on clinical efficacy or drug-drug interactions involving transporters. 
 Due to the significance of OAT1 and OAT3 within this guidance, it was apparent 
that a greater understanding of their structure, mechanism of action, and specifics of 
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substrate recognition, binding and translocation are needed. To begin to shed light on 
these aspects of substrate-transporter interactions for hOAT3, a comparative homology 
model was constructed. The prototypical hOAT3 substrate, estrone sulfate (ES), was 
docked within the model via in silico simulation to identify a potential binding pocket and 
residues critical to forming the compound-transporter binding complex. 
 Amino acids predicted to be involved in ES recognition were altered through site-
directed mutagenesis in order to evaluate their potential role in ES translocation. Wild 
type (WT) and mutated hOAT3 constructs were then expressed in Human Embryonic 
Kidney (HEK) 293 cells to allow for their functional analysis. Initial investigation revealed 
five mutants, Phe426Tyr, Phe430Tyr, Phe430Ser, Leu431Ile and Arg454Ala, supported 
significant ES accumulation as compared to parental HEK 293 cells. In addition, the 
Phe430Ser mutant exhibited a significant change in ES affinity as compared to WT 
hOAT3. The five remaining substitutions, Tyr342Phe, Tyr342Ala, Phe426Ser, Leu431Ala 
and Arg454Lys, led to complete loss of transport activity, indicating some rigidity in these 
positions in regards to ES recognition. In general, this hOAT3 homology model provides 
an in silico option to screen new drug candidates which may interact with hOAT3 and 






3B. MATERIALS AND METHODS  
 
Chemicals and Reagents - [3H] ES was purchased from PerkinElmer Life and 
Analytical Science (Waltham, MA). Unlabeled ES, probenecid, and DAPI readymade 
solution were purchased from Sigma-Aldrich (St. Louis, MO). Specific primers for 
mutation reactions were purchased from IDT (Coralville, IA). QuikChange Lightning Site-
Directed Mutagenesis Kit was purchased from Agilent Technologies (Santa Clara, CA). 
Lipofectamine transfection reagents and HyClone DMEM/High glucose medium with L-
glutamine and sodium pyruvate were purchased from Thermo Fisher Scientific (Waltham, 
MA). QIAprep spin mini- and midiprep kits were purchased from QIAGEN Inc. 
(Germantown, MD). GoTaq Green Master Mix was purchased from Promega (Madison, 
WI).  
Molecular Model Building - The recently solved crystal structure for 
Pirformospora indica high-affinity phosphate transporter, PiPT, was identified as the most 
suitable currently available template molecule and its sequence was downloaded from 
the Protein Data Bank (PDB ID: 4J05). The hOAT3 FASTA protein sequence was 
downloaded from UniProt (UniProtKB ID: Q8TCC7). Looped regions between TMD 1 & 2 
and 6 & 7 in the final crystalized form of PiPT were excluded based on their inability to 
resolve these regions [6]. In order to properly align the target (hOAT3) peptide sequence 
with the known template (PiPT) peptide sequence, hOAT3 secondary structures, 
including potential TMD helices, were predicted using PredictProtein v1 [7]. Looped 
regions between TMD 1 & 2 and 6 & 7 were excluded from hOAT3 due to lack of resolved 
sequence within the PiPT crystal structure. The curated sequences were aligned using 
the multiple sequence alignment software ClustalX v2 [8], followed by manual 
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modifications to avoid repetitive regions of non-alignment within predicted 
transmembrane helices, which would negatively impact the model building. The final 
alignment for PiPT-hOAT3 was visualized using ALINE v1.0.025 [9]. Based on this 
alignment, one hundred comparative protein models were generated, using the software 
MODELLER v9.17 [10]. The stereochemical integrity of the generated models was 
evaluated through DOPE scoring v9.17 [11,26] and Ramachandran plots (PROCHECK 
v9.17, [12]), both of which ensure bond lengths, angles, and torsions within the in silico 




Substrate Docking – An ionized, energy minimized structure for the prototypical 
hOAT3 substrate, ES, was generated using the computer-aided molecular modeling 
design tool SYBYL-X 2.1 [13]. Proper confirmation and atom type for the sketched in silico 
molecule was evaluated and followed by energy minimization based on Gasteiger-Huckel 
charges. Ligand docking studies were initiated using the docking algorithm GOLD v5.4 
provided from the Cambridge Crystallographic Data Centre [14]. Briefly, a GOLD 
configuration file was generated that referenced the previously generated one hundred 
hOAT3 models as the corresponding “receptor” and the in silico ES molecule as the 
“ligand”. A spherical region 30Å in diameter was designated , which virtually encapsulated 
the entire transporter. One thousand possible combinations were evaluated, and the top 
combination was selected based on GOLD score, DOPE score, and number of clusters. 
The specific hOAT3-ES combination was then visually inspected using SYBYL-X v2.1, 
which allows 3-D manipulation, thus permitting identification of amino acids deemed 
potentially critical for the formation of the compound-transporter complex. Further 
validation of these predicted critical amino acids was obtained using the empirical 
molecular modeling system HINT [15], which evaluates and scores the binding 




 Mutagenesis – hOAT3 constructs containing single conservative or non-
conservative substitutions at each position hypothesized to be part of the hOAT3-ES 
binding complex were generated, based upon the physiochemical properties of amino 
acids, amongst other supportive information [16]. Substitutions were introduced into 
pcDNA 3.1 (+) / V5-His-TOPO – hOAT3 plasmid (Figure 3.1) using the QuikChange 
Lightning Site-Directed Mutagenesis Kit (Agilent Technologies, Santa Clara, CA). 
Oligonucleotide primers used to introduce the mutations were designed online using 
QuikChange Primer Design software (Agilent Technologies, Santa Clara, CA, [17]) and 
reported in Table 3.1. Cycling parameters for QuikChange Mutagenesis Method were as 
follows: denature at 95°C for two min, 18 cycles of 95°C denature for 20 sec, 64°C 
annealing for 10 sec, 68°C elongation for 30 sec per kb of plasmid length (8kb plasmid, 
4 min); with a final elongation at 68°C for 5 min. Samples were subsequently incubated 






Figure 3.1 Plasmid Map of hOAT3 Template  
Full length hOAT3 cDNA sequence was subcloned into pcDNA3.1/V5-His-TOPO 
expression vector (Invitrogen, Carlsbad, CA) using BstX1/EcoRV restriction enzyme sites 





Table 3.1 Oligonucleotide primer sequences used for site-directed mutagenesis  
Position Substitution Primer Primer Sequence (5' to 3') 
Tyrosine 342 
Phenylalanine Forward  TACCGGTTTTGCCTACTTTAGTTTGGCTATGGGTG 
Reverse CACCCATAGCCAAACTAAAGTAGGCAAAACCGGTA 
Alanine Forward  TGCTACCGGTTTTGCCTACGCTAGTTTGGCTATGGGTGTG 
Reverse CACACCCATAGCCAAACTAGCGTAGGCAAAACCGGTAGCA 
Phenylalanine 426 
Tyrosine Forward  CCTATCCAGCTCCTACAGCTGCCTCTTCC 
Reverse GGAAGAGGCAGCTGTAGGAGCTGGATAGG 
Serine Forward  CCTATCCAGCTCCTCCAGCTGCCTCTTCC 
Reverse GGAAGAGGCAGCTGGAGGAGCTGGATAGG 
Phenylalanine 430 
Tyrosine Forward  GCTCCTTCAGCTGCCTCTACCTCTACACAAGT 
Reverse ACTTGTGTAGAGGTAGAGGCAGCTGAAGGAGC 
Serine Forward  GCTCCTTCAGCTGCCTCTCCCTCTACACAAGT 
Reverse ACTTGTGTAGAGGGAGAGGCAGCTGAAGGAGC 
Leucine 431 
Isoleucine Forward  CTCCTTCAGCTGCCTCTTCATCTACACAAGTGAATTATA 
Reverse TATAATTCACTTGTGTAGATGAAGAGGCAGCTGAAGGAG 
Alanine Forward  CTCCTTCAGCTGCCTCTTCGCCTACACAAGTGAATTATAC 
Reverse GTATAATTCACTTGTGTAGGCGAAGAGGCAGCTGAAGGAG 
Arginine 454 
Lysine Forward  GTAAGTAACCTGTGGACCAAGGTGGGAAGCATGGTGTCC 
Reverse GGACACCATGCTTCCCACCTTGGTCCACAGGTTACTTAC 





Position indicates native amino acid; Substitution indicates change (conservative or non-conservative) based on properties 
of amino acid position. Codon string for altered amino acid residue is indicated in bold within primer sequence.
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 Transformation – Dpn1 treated plasmids were incubated with XL10-Gold 
Ultracompetent Cells (Agilent Technologies, Santa Clara, CA). Preheated NZY+ broth 
was added after heat-pulsing the ultracompetent cells at 42°C for 30 sec, followed by 
incubation at 37°C for 1 hr with constant shaking (225RPM). After incubation, 50, 100, 
and 200μL aliquots of cells were spread onto three separate LB agar plates containing 
100 µg/mL ampicillin, adding a 200μL pool of NZY+ Broth for volumes less than 100μL to 
optimize spreading. Plates were incubated at 37°C for 16 hrs to allow adequate time for 
colony growth. Individual colonies were selected and grown in separate tubes containing 
8mL NZY+ Broth and 100 µg/mL ampicillin, followed by overnight incubation at 37°C with 
constant shaking. 
 Plasmid preparation – Mini or midi-plasmid preparation was performed following 
the manufacturer’s protocol [18] (QIAGEN, Germantown, MD). Briefly, pelleted bacterial 
cultures were resuspended, lysed, neutralized, centrifuged at 13,000RPM for 10 min and 
supernatants transferred to supplied spin columns. After binding of plasmid DNA, 
columns were thoroughly washed prior to final DNA elution. Plasmid DNA concentration 
was determined using UV-Vis Spectroscopy.  
 Sequencing – Generated hOAT3 mutants were confirmed by DNA sequencing. 
Samples were sent with respective oligonucleotide sequencing primers (Table 3.2) for 
Sanger sequencing (Genewiz, South Plainfield, NJ). Sequencing files provided through 





Table 3.2 Oligonucleotide primers used for hOAT3 DNA sequencing 
 
Primer Primer Sequence (5' to 3') 
hOAT3 Forward 1 TGGTCTTCCGCTTCCTGTG 
  
hOAT3 Forward 2 CTTAAGCTACCTGGGCC 
  
hOAT3 Reverse 1 CTAGGATCAGTCTCTGGAGG 
  





 Cell Culture – HEK 293, HEK-hOAT3 WT and HEK-hOAT3 mutant cell lines were 
maintained at 37°C with 5% CO2 in DMEM containing 10% FBS, 1% Pen-Strep (Gibco-
Invitrogen, Grand Island, NY) and 0.250 mg/mL G418. Once cells reached 80-90% 
confluency, passaging was performed. Briefly, the media was removed, cells were 
washed with 1x PBS, and followed by cell dissociation using 0.25% Trypsin-EDTA (Gibco-
Invitrogen, Grand Island, NY). Dislodged cells were resuspended in medium and 
passaged to a separate flask containing DMEM, 10% FBS, 1% Pen-Strep, and 0.250 
mg/mL G418. Cells were sub-cultured every three to four days and passages numbered 
4 through 20 were used for experiments.  
 Transfection – HEK 293 cells were grown in antibiotic-free DMEM containing 
4.5g/L D-Glucose, L-glutamine and 110 mg/L sodium pyruvate (Gibco-Invitrogen, Grand 
Island, NY) with 10% FBS at 37°C in 5% CO2 until reaching 60 to 80% confluency. Stable 
transfections were performed according to the Lipofectamine® 2000 Reagent protocol 
[19]. One day before transfection, 2.0 x 105 HEK 293 cells were seeded into 12-well tissue 
culture plates. On the day of transfection, Lipofectamine® 2000 (4µL) and OptiMEM 
medium (96µL) per transfection were incubated together for 5 min at room temperature. 
Plasmid DNA (1µg) was added to 100µL OptiMEM medium, combined with previous 
Lipofectamine® 2000/OptiMEM mixture, then incubated for 20 min at room temperature. 
After adding a fresh 1mL of medium to each well, the Lipofectamine® 2000/plasmid 
DNA/OptiMEM mixture (200µL) was added to each well and mixed gently. Cells were 
then incubated at 37°C for 24 to 48 hrs, followed by multiple weeks of antibiotic selection 




 Accumulation Assay – The procedure for cell accumulation assay has been 
described previously [20,21]. In summary, 3.5 x 105 cells were seeded with antibiotic-free 
culture medium in 24-well tissue culture plates coated with 0.1 mg/mL poly-D-lysine 48 
hrs before the experiment. The culture medium was removed and the cells were washed 
with 500μL TB for 10 min. The cells were treated with 400μLTB containing 5µM ES spiked 
with radiolabeled ES (0.25 µCi/mL [3H]ES) in the absence or presence of the inhibitor 
probenecid (500µM) for 10 min. The treatment was removed, and the cells were rinsed 
three times with ice-cold TB. Cells were lysed in 200μL 1M NaOH and shaken for 2 hrs 
at room temperature. Afterward, cells were neutralized with 250μL 1M HCl and 200μL 
10mM HEPES. Liquid scintillation was conducted using 400μL of samples with 5mL 
Ecoscint H cocktail (National Diagnostics, Atlanta, GA). Samples were normalized by 
protein content through a Bradford protein assay using 10μL sample aliquots with 200μL 
protein assay dye (Bio-Rad Laboratories, CA). Screening data were reported as mean ± 
SD from triplicate samples. 
 Kinetic Analysis Assay - Michaelis-Menten constant (Km) were determined for 
ES uptake for active hOAT3 mutants through saturation analysis according to our 
previously published protocol [21]. In summary, 3.5 x 105 cells were seeded with 
antibiotic-free culture medium in 24-well tissue culture plates coated with 0.1 mg/mL poly-
D-lysine 48hrs before the experiment. Culture medium was removed and the cells were 
washed with 500μL TB for 10 min. Cells were treated with 300μL TB containing increasing 
concentrations of ES (1µM – 100µM; 0.25 µCi/mL [3H]ES) for one min. The treatment was 
removed and samples processed as described above for the accumulation assay. Data 
were plotted and analyzed by non-linear regression to generate Km estimates (GraphPad 
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v8.3.0). Kinetic data were reported as mean ± SD from triplicate samples. Final Km 
estimates were reported as mean ± SE from a minimum of three separate experiments 
Verification of Genomic Integration – Cells were suspended in 500μL of lysis 
buffer (1 M Tris (pH 8.0), 5 M NaCl, 0.5 M EDTA, 10% SDS, and 0.4 mg/mL proteinase 
K) and incubated at 55°C overnight while shaking at 200RPM. The following day, genomic 
DNA was extracted using an equal volume of phenol/chloroform/isoamyl alcohol (25:24:1) 
and shaking for 10 min. Samples were centrifuged for 10 min at 15,000RPM in a table-
top microcentrifuge. The upper aqueous phase was collected, mixed with an equal 
amount of isopropyl alcohol, and spun for an additional 15 min to obtain a DNA pellet. 
The pellet was rinsed with 70% ethanol, air-dried, and re-suspended in 200μL TE buffer 
(pH 8.0) containing 10mM Tris and 1mM EDTA. DNA concentration was determined using 
UV-Vis Spectroscopy. Genomic DNA ranging from 150 to 1,000ng, 2x GoTaq Green 
Master Mix (25μL), and 2.5μL primer pair mix (100μM T7: 5’ – 
TAATACGACTCACTATAGGG – 3’; 100μM hOAT3Rev1: 5’ – 
CTAGGATCAGTCTCTGGAGG– 3’) were added to a final volume of 50μL and run in a 
thermocycler under the following conditions: denature at 95°C for 2 min, 30 cycles of 
denaturation at 95°C for 30 sec, annealing at 52°C for 30 sec, elongation at 72°C for one 
min. Final elongation proceeded at 72°C for 5 min, then samples were held at 4°C. PCR 
products were loaded onto a 1% agarose gel for separation using electrophoresis at 120V 
for 1 hr. Gel was stained in EtBr for 10 min and visualized using ChemiDoc Touch Imaging 
System (Bio-Rad Laboratories, Hercules, CA).  
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 Mycoplasma Testing – All cell lines were tested for the presence of mycoplasma 
using a Universal Mycoplasma Detection Kit (ATCC, Manassas, VA). Briefly, adherent 
cells were harvested and resuspended in lysis buffer, heated at 95°C, then spun at 
13,000RPM for 5 min. Supernatants were collected, followed by the addition of Universal 
PCR mix plus Universal Primers supplied through the kit, with the appropriate positive 
and negative controls. Following the PCR amplification procedure, a 3% agarose gel was 
prepared, and 10μL of PCR products were loaded. The gel was stained using EtBr, 
washed thrice in diH2O, then observed under UV illumination. No instances of 
mycoplasma were detected in any generated HEK hOAT3 expressing cell lines (Figure 
3.2). 
Statistics – Data are plotted as mean ± SD for initial screening assay and 
individual saturation assays. Final Km estimates are reported as mean ± SE. Statistical 
analysis was performed using GraphPad Prism v8.3.0 and R 3.6.0. Equal variance, one-
way ANOVA with post-hoc Dunnett’s multiple comparisons was used to evaluate 
differences compared to a single control where indicated. All differences were considered 
statistically significant if p < 0.05.  
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Figure 3.2 Mycoplasma Testing of Generated HEK cell lines 
Mycoplasma testing of HEK hOAT3 cell lines along with parental HEK 293 cells is shown. 
10μL aliquots were loaded for 100bp DNA ladder, positive control, negative control, and 
HEK cell lines. Mycoplasma was detected for positive control only (Lane 2, 464bp). Lanes 
are as follows: (1) 100bp DNA Ladder, (2) Positive Control, (3) Negative Control, (4) 
hOAT3 WT, (5) HEK 293, (6) hOAT3 Tyr342Phe, (7) hOAT3 Tyr342Ala, (8) hOAT3 
Phe426Tyr, (9) hOAT3 Phe426Ser, (10) hOAT3 Phe430Tyr, (11) hOAT3 Phe430Ser, 
(12) hOAT3 Leu431Ile, (13) hOAT3 Leu431Ala, (14) hOAT3 Arg454Lys, (15) hOAT3 






Comparative Modeling of hOAT3 
 
 An initial BLAST search of the non-redundant protein sequences database was 
performed using hOAT3 as the target to identify a suitable template for homology 
modeling. Search results indicated the peptide sequence of the recently crystalized 
protein, PiPT, shares 31% sequence similarity and 17% sequence identity with hOAT3, 
signifying PiPT as a more appropriate template than previously utilized GlpT (PDB ID: 
1PW4), which shares 27% similarity and 16% identity with hOAT3. In addition to higher 
similarity and identity, PiPT offers further advantages as a template molecule such as 
being a eukaryotic protein, inclusion in the MFS, a 12 TMD structure divided into two 
domains, and being crystallized in the occluded state therein maximizing the interaction 
within the compound-transporter complex. Thus, PiPT was selected to serve as the 
template. 
Both PiPT and hOAT3 are predicted to have large sequence loops between TMDs 
1 & 2 and 6 & 7. Due to their flexibility, these loops are not resolved in the PiPT crystal 
structure, thus there are no corresponding residues to model. Therefore, before alignment 
of hOAT3 and PiPT peptide sequences, the hOAT3 sequence (UniProtKB ID: Q8TCC7) 
was truncated from Gln38 - Asn117 (between TMDs 1 & 2) and Val264 – Arg319 
(between TMDs 6 & 7). The final sequence alignment is shown in Figure 3.3, showing the 
TMDs for PiPT (white) and hOAT3 (red) as well as exact positioned identities (white 
letters). This alignment file was fed into MODELLER, generating 100 separate in silico 
homology models for hOAT3.  
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Next, docking studies were conducted using GOLD v5.4 where the energy 
minimized ES structure was docked into each model separately, ten times, generating a 
total of 1,000 different combinations between hOAT3 and ES. To determine the top 
hOAT3-ES combination, models were ranked through evaluation of their DOPE and 
GOLD scores, as well as cluster analysis. As shown in Table 3.3, the top hOAT3 model 
was number 1 with ES pose number 2. Overall, this combination had the highest GOLD 
score (69.38), a similar DOPE score to other top combinations (-44379.79), and the 
second highest number of clusters (11) of all other GOLD ranked solutions reported. To 
further evaluate hOAT3 model 1, a Ramachandran plot was generated using the program 
PROCHECK v9.17 allowing visualization of all bond angles. Favorable bond angles 
appear in the red and yellow regions whereas disallowed angles are located in the white 
areas (Figure 3.4). Only four residues, Leu3, Arg65, Ser159, and Tyr216 were identified 
as forming unfavorable bond angles in this model. These residues are positioned on the 
outskirts of the in silico model, i.e. well outside the putative ES binding domain, and thus 
likely exert no direct influence on the hOAT3-ES binding complex in this model. It was 
also of interest to visualize all top ES solutions docked, to better validate the top model 
chosen (Figure 3.5). The top ES pose is displayed as a space-filling molecule to 
distinguish from all other ES molecules docked. This molecule is positioned centrally 
within hOAT3, clustered amongst numerous additional ES molecules that were separately 
docked. This provides further validation that the top ES pose (2) is an appropriate 
representation of the GOLD docking results generated, in addition providing further 
support to a clear single, centralized binding region. Thus, hOAT3 model 1 was selected 
as the best representation of hOAT3 in the occluded state with ES (Figure 3.6). As shown, 
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the generated hOAT3 model has 12 predicted TMDs with intracellular amino and carboxyl 
termini, with multiple TMDs contributing to the binding pocket. ES is represented with a 




Figure 3.3 Peptide Sequence Alignment Between PiPT and hOAT3 
Final peptide sequence alignment between PiPT (top) and hOAT3 (bottom). TMD regions 
for PiPT (white) documented and confirmed through crystallization of the protein. TMD 
regions for hOAT3 were initially predicted through PredictProtein v1 software, then 
regions were determined (red) upon final model generation. White letters indicate 
conserved amino acid residues between target and template. Image generated using the 
program ALINE v1.0.025.  
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1 69.38 1 2 -44379.79 11 
2 68.05 23 7 -44802.35 5 
3 66.61 44 8 -44684.35 4 
4 66.36 97 4 -44953.14 6 
5 63.76 59 28 -45154.92 1 
6 61.97 6 27 -44260.03 1 
7 61.54 40 15 -45136.84 2 
8 61.25 37 9 -45301.54 4 
9 60.33 35 1 -44745.46 14 
10 59.26 88 21 -44779.84 1 
11 59.12 48 10 -44982.47 3 
12 58.73 9 13 -44662.20 2 
13 57.62 66 5 -44582.02 6 
14 55.34 18 31 -44978.31 1 







Figure 3.4 Ramachandran Plot of Top hOAT3 Homology Model 
Axes indicate degree value of rotatable bonds present between neighboring amino acid 
residues with specific model generated. High percentage of amino acid residues were 
reported within favorable regions (98.7%), with remaining residues (LEU3, ARG65, 






Figure 3.5 Summary of All ES Docked Poses with hOAT3 
Summary of all ES locations upon successful GOLD docking studies. The ES locations 
for all modeling studies are indicated as line molecules. The top ES location (pose 2) is 
shown as a space filling molecule. The multicolored helices represent the 12 TMD regions 




Using PyMOL v1.8, further analysis was focused within the suggested binding 
pocket to determine which amino acid contacts within the transporter are critical to ES 
recognition (Figure 3.7 A & B). Five amino acids with potential ES interactions were 
identified, specifically Tyr342, Phe426, Phe430, Leu431, and Arg454. The nature of the 
proposed interactions between each residue and ES are summarized in Table 3.4. An 
edge-face aromatic interaction was predicted for Tyr342. Phe426, Phe430 and Leu431 
were proposed to exhibit hydrophobic interactions. Finally, a bidentate hydrogen bond 
interaction was identified for Arg454. To directly examine these predicted amino acid–ES 
interactions, conservative and non-conservative substitutions were introduced at each 







Figure 3.6 Three-Dimensional in silico hOAT3-ES Model 
Three-dimensional side view (left) and top view (right) of the generated hOAT3-ES 
binding complex. The multicolored helices represent the 12 TMD regions for hOAT3 and 
are numbered in the top view. A space filling representation of ES is shown with putative 








The five amino acids predicted to be important for ES binding and transport are indicated. 








Figure 3.7 A & B Different Rotational Views of the hOAT1-ES Binding Complex 
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Table 3.4 Summary of putative ES-hOAT3 complex forming amino acids, the 
predicted nature of each interaction and generated conservative and non-
conservative hOAT3 mutations 
TMD Amino Acid Interaction Conservative 
Non-
conservative 
7 Tyr342 Edge-Face Aromatic Phe Ala 
10 Phe426 Hydrophobic  Tyr Ser 
10 Phe430 Hydrophobic  Tyr Ser 
10 Leu431 Hydrophobic Ile Ala 
11 Arg454 Salt Bridge featuring Bidentate Hydrogen Bond Lys Ala 
 
Interactions proposed are based on each amino acid’s orientation with the docked 
substrate. Conservative and non-conservative substitutions were based on 




In Vitro Testing 
 
 The identity of all hOAT3 mutant constructs was confirmed by DNA sequencing 
prior to functional examination. Representative chromatograms for both a hOAT3 
conservative (Tyr342Phe) and non-conservative (Tyr342Ala) mutation are shown. In 
Figure 3.8 panel A the WT ‘TAT’ codon for tyrosine is clearly observed, while in panel B 
the codon has been mutated to ‘TTT’ which codes for phenylalanine. Similarly, in Figure 
3.9 it can be seen that the WT tyrosine codon has been altered to ‘GCT’ which codes for 









Figure 3.8 Representative Chromatogram for DNA Sequencing Confirmation of 
hOAT3 Conservative Mutants. 
The chromatogram for hOAT3 WT (A) and hOAT3 Tyr342Phe (B) sequence. The triplet 
codon region highlighted shows position of mutation. The three letter amino acid codon 








Figure 3.9 Representative Chromatogram for DNA Sequencing Confirmation of 
hOAT3 Non-conservative Mutants. 
The chromatogram for hOAT3 WT (A) and hOAT3 Tyr342Ala (B) sequence. The triplet 
codon region highlighted shows position of mutation. The three letter amino acid codon 





After establishing stably-expressing WT and mutated hOAT3 cell lines, initial 
accumulation assays were performed to quantify ES transport activity. Cells were 
exposed to ES (5µM) in the absence or presence of the inhibitor probenecid (Figure 3.10). 
As shown, hOAT3 WT cells showed marked accumulation of ES (~17 fold) compared to 
HEK 293 parental cells (192.6 ± 5.9 vs. 11.0 ± 2.5 pmol/mg protein/10 min, respectively). 
The known hOAT3 inhibitor probenecid (500µM) showed virtually complete inhibition of 
hOAT3-mediated ES uptake, as accumulation was comparable between probenecid 
exposed hOAT3 WT cells and HEK 293 parental cells (9.9 ± 0.8 vs. 7.6 ± 0.5 pmol/mg 
protein/10 min, respectively). Cell accumulation assay demonstrated that substitutions 
Phe426Tyr (100.2 ± 4.7 pmol/mg protein/10 min), Phe430Tyr (338.6 ± 7.2 pmol/mg 
protein/10 min), Phe430Ser (155.3 ± 5.7 pmol/mg protein/10 min), Leu431Ile (27.7 ± 2.7 
pmol/mg protein/10 min) and Arg454Ala (21.7 ± 7.2 pmol/mg protein/10 min) all retained 
ES transport activity as compared to HEK 293 parental cells. Two conservative 
(Tyr342Phe, Arg454Lys) and three non-conservative (Tyr342Ala, Phe426Ser, 
Leu431Ala) substitutions abolished ES transport mediated by hOAT3. To determine if 
hOAT3 mutant cell lines were considered transport active or inactive, equal variance 
ANOVA with Dunnett’s multiple comparison between hOAT3 mutant cell lines and HEK 
293 parental background cells was performed. Three cell lines (Phe426Tyr, Phe430Tyr, 
Phe430Ser) were found to be statistically different from HEK 293 (p < 0.0001), along with 
Leu431Ile (p < 0.001) and Arg454Ala (p < 0.05), suggesting these five are transport active 
mutants. However, despite reaching statistical significance under these conditions, it is 
clear that the Leu431Ile and Arg454Lys cell lines did not exhibit significant inhibitor-
sensitive ES uptake (i.e., no hOAT3 transporter-mediated uptake) and it was concluded 
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these should be treated as false positives, and they were not considered active mutants. 
The remaining cell lines (Tyr342Phe, Tyr342Ala, Phe426Ser, Leu431Ala, Arg454Lys) 





Figure 3.10 Initial ES Transport Activity Assay Assessment of hOAT3 Mutants 
Initial accumulation assay with 5µM ES in the absence (black) and presence (white) of 
500µM probenecid. Y-axis labels indicate the hOAT3 protein expressed in the stable cell 
line tested including hOAT3 WT (hOAT3), parental background (HEK 293), and the 
generated conservative and non-conservative hOAT3 mutants. Accumulation was 
performed over a 10 min period and corrected by protein content. Values reported as 
mean ± SD of triplicate samples. Significance indicated by ****p < 0.0001, ***p < 0.001, 
*p < 0.05 as determined by one-way ANOVA followed by Dunnett’s t-test in comparison 




For the true active hOAT3 mutant cell lines, further kinetic analysis was conducted 
to determine if mutant cells exhibited changes in ES affinity (Km) as compared to hOAT3 
WT. Cells were exposed to increasing concentrations of ES (1µM – 100µM) for one 
minute and representative plots are shown in Figure 3.11. All constructs exhibited 
saturable transport activity and final Km estimates are summarized in Table 3.5. As 
shown, Km estimates for ES on the hOAT3 mutants Phe426Tyr, Phe430Tyr and 
Phe430Ser all trended higher, i.e., showed decreased affinity (13.4 ± 2.9, 13.6 ± 0.2 µM, 
and 26.8 ± 5.0 respectively). However, only the Phe430Ser mutant (26.8 ± 5.0 µM) had 





A; HEK hOAT3 WT B; HEK hOAT3 Phe426Tyr 
C; HEK hOAT3 Phe430Ser D; HEK hOAT3 Phe430Tyr 
Figure 3.11 Saturation Analysis Conducted for hOAT3 WT and Active Mutants 
One minute uptake of increasing concentrations of ES (1µM – 100µM) spiked with 
radiolabeled [3H] ES (0.25 µCi/mL) in (A) HEK hOAT3 WT, (B) HEK hOAT3 Phe426Tyr, 
(C) HEK hOAT3 Phe430Ser, and (D) HEK hOAT3 Phe430Tyr cell lines. Data were 
corrected for background measured in HEK 293 control cells. Km values were determined 
using Michaelis-Menten nonlinear regression using GraphPad Prism. Experiments within 
each cell line were repeated a minimum of three times in triplicate with final Km estimates 
reported as mean ± SE. Each panel consists of a representative curve, with values plotted 




Table 3.5 Estimated Km for hOAT3 WT and hOAT3 active mutants 
Transporter Km (µM) N 
hOAT3 WT 9.1 ± 2.6 3 
hOAT3 Phe426Tyr 13.4 ± 2.9 3 
hOAT3 Phe430Tyr 13.6 ± 0.2 3 
hOAT3 Phe430Ser 26.8 ± 5.0* 5 
 




Genomic Integration of hOAT3 Mutant Constructs 
To confirm successful transfections of transport inactive cell lines, genomic DNA 
from each transfected cell lines was isolated and used as template for PCR. Primers 
consisted of the plasmid sequence specific T7 primer and the hOAT3 reverse 1 
sequencing primer (Table 3.2) which should yield full length (~2,000bp) amplification of 
the hOAT3 insert. As shown in Figure 3.12, the expected product band was detected in 
every instance, except for non-transfected HEK 293 negative control (lane 2), confirming 
successful genome integration of all constructs during transfection. 
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Figure 3.12 Confirmation of Construct Integration into Genomic DNA 
Confirmation of successful genomic integration of mutant hOAT3 constructs. Lanes are 
as follows: (1) 1kb Ladder, (2) HEK 293, (3) hOAT3 WT, (4) hOAT3 Tyr342Phe, (5) 
hOAT3 Tyr342Ala, (6) hOAT3 Phe426Tyr, (7) hOAT3 Phe426Ser, (8) hOAT3 Phe430Tyr, 
(9) hOAT3 Phe430Ser, (10) hOAT3 Leu431Ile, (11) hOAT3 Leu431Ala, (12) hOAT3 








Although it has been over two decades since the first discovery of OATs, 
information is still lacking in regards to the structural components that impact compound 
recognition at the molecular level. Thus far, attempts to crystallize SLC22 family members 
have been unsuccessful, thus, homology modeling has been employed. Recently, 
however, a protein within the MFS, PiPT, was crystallized and represents a suitable 
template for hOAT3 modeling studies. PiPT belongs to the same transporter superfamily, 
shares higher protein sequence identity (17%) and similarity (31%) with hOAT3 than GlpT 
(16% and 27%, respectively) upon BLAST analysis, and is more closely related 
evolutionarily as it is a eukaryotic protein whereas GlpT is prokaryotic. Therefore, in this 
work molecular modeling studies were conducted using PiPT as template.  
One hundred models were constructed to represent the proposed alignment 
between PiPT and hOAT3, which aids in distinguishing small bond angles and torsional 
rotations over the course of the model building procedure. Of these potential 1,000 
combinations generated, the top 15 results are reported in Table 3.3. The best 
combinations between hOAT3 and ES are listed in descending order of “GOLD Rank”. 
Selecting which model and pose combination to continue with was based on GOLD 
scores, DOPE scores, and number of clusters. Based upon these criteria, hOAT3 model 
1 was selected (out of 100), and the best pose of ES within this model was number 2. 
Further evaluation of model 1 was conducted via Ramachandran plot analysis. Such 
analysis provides an additional detailed check on the stereochemistry of the protein 
structure in the proposed model (Figure 3.4). This plot provides assessment of the overall 
quality of the structure and also highlights regions which may require further investigation 
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[12]. As indicated, in model 1, 98.7% of the residues exist in “allowable” or “favorable” 
conformations and only four residues, Leu3, Arg65, Ser159, and Tyr216, were identified 
as having inappropriate bond angles between neighboring amino acids. Further visual 
inspection of the model confirmed these four residues reside towards the outer surface 
of the protein, a significant distance from the putative ES binding domain identified herein. 
Therefore, these residues were viewed as likely being non-influential to the final hOAT3-
ES result. Finally, when all 1,000 ES docking results were observed as a group it was 
clear a single, centralized binding region emerged and the top ES pose (i.e, pose 2, 
displayed as a space-filling molecule to distinguish from all other ES molecules docked) 
is positioned within this centrally located region within hOAT3 (Figure 3.5). Thus, model 
1 was selected (Figure 3.6).  
 Side (left) and top (right) views of the generated hOAT3 model illustrate the 12 
TMD regions, along with the proposed binding pocket ES occupies (indicated by the grey 
space-filling cluster). Initial investigation revealed amino acid residues predicted to 
interact with ES, and they are labeled and visualized in Figure 3.7 A & B. One residue, 
Tyr342, may exhibit an edge-face aromatic interaction, as the dense positive charge 
about the edge of the benzene ring of the tyrosine is orientated toward the electronegative 
sulfate within the ES (Table 3.4). Arg454 has the potential for hydrogen bonding, as the 
guanidinium group aligns with the electronegative sulfate group of ES (Figure 3.7 A). 
Three residues, Phe426, Phe430, and Leu431, may exhibit hydrophobic interactions, i.e., 
the nonpolar properties of the listed residues associate with the tetracyclic ring within ES, 
thus forming in a hydrophobic pocket (Figure 3.7 B).  
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In order to test whether the residues identified in the current study truly impact 
hOAT3-ES interactions, conservative and non-conservative amino acid substitutions 
were introduced (Table 3.4). Initial transport activity assays confirmed five hOAT3 
mutants, Phe426Tyr, Phe430Tyr, Phe430Ser, p < 0.0001; Leu431Ile, p < 0.001; 
Arg454Ala, p < 0.05) exhibited ES accumulation that was significantly greater than HEK 
293 parental background (Figure 3.10). However, Leu431Ile and Arg454Ala, were 
identified as false positives in that they did not support significant inhibitor-sensitive ES 
uptake. All other mutants were determined to be transport inactive, as ES accumulation 
was not significantly different from background. Three non-conservative substitutions 
(Tyr342Ala, Phe426Ser, Leu431Ala) led to inactivity. This was likely due to the drastic 
change of the initial amino acid to either alanine or serine, residues devoid of a 
physiochemical influencing functional group, thus limiting the potential interaction with the 
substrate, ES. Two conservative substitutions, Tyr342Phe and Arg454Lys, where also 
inactive, potentially indicating the importance of tyrosine and arginine at these positions; 
e.g. the edge-face Pi system (Tyr342) and the hydrogen bond (Arg454) between them 
and ES is crucial for ES translocation and altering these residues disrupts substrate 
recognition. 
While the three active hOAT3 mutants recognized and transported ES to some 
degree, it was unknown whether mutation led to altered affinity for ES. Therefore, these 
mutants were subjected to saturation (kinetic) analysis in order to estimate the Km for ES 
and directly compare this to the hOAT3 WT Km (Figure 3.11). The hOAT3 WT Km for ES 
determined in these studies was 9.1 ± 2.6µM, which is in good agreement with the 
previous literature [40]. Estimated Km values for both Phe426Tyr and Phe430Tyr trended 
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higher (13.4 ± 2.9 and 13.6 ± 0.2µM, respectively), while Phe430Ser had a significantly 
larger Km value of 26.8 ± 5.0µM, indicating the importance of phenylalanine at this position 
for efficient ES translocation (Figure 3.11 and Table 3.5). Further studies will investigate 
if multiple substitutions within the same molecule (i.e., double or triple mutants) will result 
in further changes in transporter affinity.  
 Several explanations exist for the lack of ES transport activity by Tyr342Phe, 
Tyr342Ala, Phe426Ser, Leu431Ala, and Arg454Lys; 1) failed integration of full length 
hOAT3-cDNA into the genomic DNA during transfection, 2) substitution disrupted of the 
native amino acid truly impacted substrate recognition based on a critical interaction with 
ES, or 3) substitution disrupted proper folding and/or targeting of the protein to the plasma 
membrane following translation. Genomic integration of intact cDNA for all hOAT3 
constructs was confirmed by PCR (Figure 3.12), demonstrating at the very least 
successful genomic integration. In order to examine targeting of inactive hOAT3 mutants 
to the membrane surface, multiple techniques were considered, similar to the approach 
used with hOAT1. Techniques include: developing a hOAT3-GFP plasmid, developing a 
hOAT3-c-Myc plasmid for continued IHC analysis, and generating stable HEK cell lines 
expressing hOAT3-c-Myc plasmid followed by detection through Western blotting. 
However, due to lack of targeting success for hOAT1, progress was halted for hOAT3 
until a successful method for membrane targeting of hOAT1 is confirmed and validated, 
then it would be feasible to shift toward hOAT3. There are additional published methods 
which validated targeting of hOAT3 to the membrane [34], however, the hOAT3 antibody 
was generated “in-house” therefore not available commercially. Future studies to prove 
membrane targeting include the use of biotinylation in conjunction with a commercial 
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antibody to target hOAT3 or a targeted proteomics approach for detection/quantification 
[32,33]. 
In summary, a novel in silico homology model for hOAT3 based on the solved 
structure of PiPT was successfully constructed and validated. Upon successful docking 
of the prototypical substrate, ES, into the generated hOAT3 model, residues Tyr342, 
Phe426, Phe430, Leu431, and Arg454 (involving three separate TMDs) were identified 
as potentially critical to ES recognition. Preliminary data demonstrated that non-
conservative substitution to alanine or serine led to complete loss of transport activity in 
all but one hOAT3 mutant (Phe430Ser). Conservative substitutions at positions 426 and 
430 did not significantly alter transport affinity for ES, demonstrating a degree of tolerance 
at these positions in hOAT3 without loss of transporter function. The significantly reduced 
transport affinity for the non-conservative substitutions at position 430 suggests that there 
is less flexibility at this position or that phenylalanine is required at this position for 
effective ES transport. Future work will be focused on confirming non-functional hOAT3 
mutants in regards to membrane targeting efforts to further strengthen our conclusions. 
Once confirmed, hOAT3 modeling studies could pave the way to optimizing drug design, 
by serving as a preliminary tool to assess initial validation of new chemical entities, in 
addition to predicting drug-drug interactions, prior to investing marked time, money, and 




CHAPTER 4 – MODELING ACROSS hOAT1-3 
 





The SLC22 transporter family consists of organic cation, anion, and zwitterion 
transporters. Within this family lies OAT1 (SLC22A6) and OAT3 (SLC22A8), two OATs 
which were previously mentioned in Chapters 2 and 3, as well as OAT2 (SLC22A7), 
initially identified in rat liver [41] followed by mRNA isolation within human kidney and liver 
[42]. Sun et al. reported that hOAT2 had 39% and 38% identity among deduced amino 
acid sequences of hOAT1 and hOAT3, as compared to the 51% identity hOAT1 and 
hOAT3 share. These differences in shared identity may be the basis for differing 
substrate/inhibitor profiles amongst hOAT1-3, as well as account for greater overlap 
between hOAT1 and 3 vs hOAT2 in substrate recognition. For example, does probenecid, 
a pan inhibitor of hOAT1-3, exhibit conserved contacts amongst all three paralogs, while 
PAH, a preferred hOAT1 substrate, exhibits strong contacts within the hOAT1 model that 
are absent in hOAT2 and 3. Thus, it was of interest to generate a dataset of structurally 
diverse OAT family substrates/inhibitors to screen across the constructed hOAT1, 2 and 
3 homology models to (1) determine if there were common contacts shared between 
compounds within each transporter model and (2) determine if there were notable 
commonalities/differences in contacts across hOAT1-3 for the structurally diverse 
dataset. Such information may partially explain certain variations in compound recognition 
and affinity across OAT paralogs. 
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Homology models for hOAT1 and hOAT3 have been previously generated using PiPT 
as template, using PAH and ES as the prototypical substrates. This in silico model 
building information was used as a guide for generating a hOAT2 homology model, once 
again with PiPT as template. Further evaluation of the generated hOAT1-3 models were 
conducted by additional docking of structurally diverse compounds. These compounds 
include the antiviral agent, acyclovir; the β-lactam antibiotic, penicillin G; the non-steroidal 
anti-inflammatory drug, salicylate; the prototypical inhibitor for OATs, probenecid; the 
counter ion used to drive anion exchange on OATs, alpha-ketoglutarate (α-KG); the 
fluorescent moiety, fluorescein; along with PAH and ES, the prototypical substrates for 
hOAT1 and hOAT3, respectively. Each compound was individually docked within the 
hOAT1-3 homology models and amino acid residues deemed critical within the 
prospective binding complexes were identified. This analysis of docking known 
compounds with varying structures within hOAT1-3 provided further information regarding 




4B. MATERIALS AND METHODS 
 
Molecular Model Building – The recently solved crystal structure for PiPT was 
identified as the most suitable currently available template molecule and its sequence 
was downloaded from PBD (PDB ID: 4J05). The hOAT2 FASTA protein sequence was 
downloaded from UniProt (UniProtKD ID: Q9Y694). Looped regions between TMD 1 & 2 
and 6 & 7 in the final crystalized form of PiPT were excluded based on their inability to 
resolve these regions [6]. In order to properly align the target (hOAT2) peptide sequence 
with the known template (PiPT) peptide sequence, hOAT2 secondary structures, 
including potential TMD helices, were predicted using PredictProtein v1 [7]. Looped 
regions between TMD 1 & 2 and 6 & 7 were excluded from hOAT2 due to lack of resolved 
sequence within the PiPT crystal structure. The curated sequences were aligned using 
the multiple sequence alignment software ClustalX v2 [8], followed by manual 
modifications to avoid repetitive regions of non-alignment within predicted 
transmembrane helices, which would negatively impact the model building. The final 
alignment for PiPT-hOAT2 was visualized using ALINE v1.0.025 [9]. Based on this 
alignment, one hundred comparative homology models were generated, using the 
software MODELLER v9.17 [10]. The stereochemical integrity of the generated models 
was evaluated through DOPE scoring v9.17 [11,26] and Ramachandran plots 
(PROCHECK v9.17, [12]), both of which ensure bond lengths, angles, and torsions within 
the in silico model were within acceptable and feasible limits. Note that hOAT1 and 





Substrate Docking – The ionized, energy minimized structures for the following 
compounds were generated (Figure 4.1) using the computer-aided molecular modeling 
design tool SYBYL-X 2.1 [13]. Proper confirmation and atom type for the sketched in silico 
molecules were evaluated and followed by energy minimization based on Gasteiger-
Huckel charges. Ligand docking studies were initiated using the docking algorithm GOLD 
v5.4 provided from the Cambridge Crystallographic Data Centre [14]. Briefly, GOLD 
configuration files were generated individually which referenced the previously generated 
one hundred hOAT1 - 3 models as the corresponding “receptor” and the in silico 
compound as the “ligand”. A spherical region 30Å in diameter was designated, which 
virtually encapsulated the entire transporter. One thousand possible combinations were 
evaluated, and the top combination was selected based on GOLD score, DOPE score, 
and number of clusters. The specific hOAT - compound combinations were then visually 
inspected using SYBYL-X v2.1, which allows 3-D manipulation, thus permitting 
identification of amino acids deemed potentially critical for the formation of the compound-
transporter complex. Further validation of these predicted critical amino acids was 
obtained using the empirical molecular modeling system HINT [15], which evaluates and 











Comparative Modeling of hOAT1, 2, & 3 
An initial BLAST search of the non-redundant protein sequences database was 
performed to identify a suitable template for homology modeling. As mentioned 
previously, PiPT shares 33% sequence similarity and 19% sequence identity with hOAT1, 
and 31% sequence similarity and 17% sequence identity with hOAT3, both larger 
percentages then the previously utilized GlpT (27% and 16%). As for hOAT2, PiPT shares 
33% sequence similarity and 19% sequence identity, signifying PiPT as a more 
appropriate template than GlpT, which shares 30% similarity and 18% identity with 
hOAT2. In addition, PiPT offers further advantages as a template molecule such as being 
a eukaryotic protein, inclusion in the MFS, a 12 TMD structure divided into two domains, 
and being crystallized in the occluded state therein maximizing the interaction within the 
compound-transporter complex. Thus, PiPT was selected to serve as the template. 
All three hOATs and PiPT are predicted to have large sequence loops between 
TMDs 1 & 2 and 6 & 7. Due to their flexibility, these loops are not resolved in the PiPT 
crystal structure, thus there are no corresponding residues to model. Previous sequence 
curation was performed for hOAT1 and hOAT3, thus the procedure was repeated for 
hOAT2. Therefore, before alignment of hOAT2 and PiPT peptide sequences, the hOAT2 
sequence (UniProtKB ID: Q9Y694) was truncated from Ala54 - Glu139 (between TMDs 
1 & 2) and Leu286 – Phe338 (between TMDs 6 & 7). The final sequence alignment is 
shown in Figure 4.2, indicating the TMDs for PiPT (white) and hOAT2 (green) as well as 
exact positioned identities (white letters). This alignment file was fed into MODELLER, 
generating 100 separate in silico homology models for hOAT2. 
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Next, docking studies were conducted using GOLD v5.4 where each energy 
minimized compound was docked into each model separately, ten times, generating a 
total of 1,000 different combinations for each compound within each model. To determine 
the top compound-transporter combination, models were ranked through evaluation of 
their DOPE and GOLD scores, as well as cluster analysis. This process was previously 
summarized for hOAT1 and hOAT3 using their prototypical substrates (PAH and ES, 
respectively). As for hOAT2, representative analysis was performed to determine the top 
hOAT2-PAH combination. As shown in Table 4.1, the top hOAT2 model was number 18 
with PAH pose number 10. Overall, this combination had the highest GOLD score (62.67), 
a similar DOPE score to other top combinations (-43299.80), and the highest number of 
clusters of the top five combinations (3). To further evaluate hOAT2 model 18, a 
Ramachandran plot was generated using the program PROCHECK v9.17 allowing 
visualization of all bond angles. Favorable bond angles appear in the red and yellow 
regions whereas disallowed angles are located in the white areas (Figure 4.3). Only one 
residue, Arg183, was identified as forming unfavorable bond angles in this model. This 
residue was positioned on the outskirts of the in silico model, i.e. well outside the putative 
PAH binding domain, and thus unlikely to exert direct influence on the hOAT2-PAH 
binding complex in this model. Thus, hOAT2 model 18 was selected as the best 
representation of hOAT2 in the occluded state with PAH. This process was repeated for 
hOAT1, 2, and 3 for each ionized, energy minimized compound (Figure 4.1), and top 
hOAT model and compound combinations were selected (Figures 4.4 – 4.6). Each 
compound is represented as a space filling molecule in a separate color and panel, 
specifically acyclovir (yellow), α-KG (grey), ES (pink), fluorescein (green), PAH (orange), 
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penicillin G (red), probenecid (purple) and salicylate (blue). Potential individual amino acid 
contacts are represented with lines. hOAT1-PAH and hOAT3-ES homology models are 






Figure 4.2 Peptide Sequence Alignment Between PiPT and hOAT2 
Final peptide sequence alignment between PiPT (top) and hOAT2 (bottom). TMD regions 
for PiPT (white) documented and confirmed through initial crystallization of the protein. 
TMD regions for hOAT2 were initially predicted through PredictProtein v1 software, then 
regions were determined (green) upon final model generation. White letters indicate 
conserved amino acid residues between target and template. Image generated using the 
program ALINE v1.0.025. 
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1 62.67 18 10 -43299.80 3 
2 59.57 29 21 -42779.56 2 
3 58.68 72 14 -42883.64 2 
4 57.89 55 8 -43178.04 3 
5 57.60 46 38 -43666.20 1 
6 56.92 61 3 -42813.39 6 
7 56.20 32 6 -42801.71 4 
8 55.76 93 17 -43566.15 2 
9 55.35 66 5 -43196.99 4 
10 55.25 88 1 -42366.45 7 
11 55.07 64 11 -43690.71 3 
12 54.07 85 20 -43167.59 2 
13 53.55 35 12 -43004.50 3 
14 53.24 70 28 -42987.27 1 







Figure 4.3 Ramachandran Plot of Top hOAT2 Homology Model 
Axes indicate degree value of rotatable bonds present between neighboring amino acid 
residues with specific model generated. High percentage of amino acid residues were 
reported within favorable regions (99.7%), with remaining residue (ARG183) in 
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Compounds docked within hOAT1 include (A) acyclovir, (B) α-KG, (C) 
ES, (D) fluorescein, (E) penicillin G, (F) probenecid, and (G) salicylate. 
Docked compound shown as space filling molecule within binding 
pocket, with potential amino acid contacts shown as line molecules. 
PAH is absent since it has been docked previously (Figure 2.8 and 
Figure 2.9 A & B). Image files generated using PyMOL 1.8. 
 Figure 4.4 Top Docking Solutions for Compound Dataset within hOAT1 
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Compounds docked within hOAT2 include (A) 
acyclovir, (B) α-KG, (C) ES, (D) fluorescein, (E) 
PAH, (F) penicillin G, (G) probenecid, and (H) 
salicylate. Docked compound shown as space 
filling molecule within binding pocket, with 
potential amino acid contacts shown as line 
molecules. Image files generated using PyMOL 
1.8. 
Figure 4.5 Top Docking Solutions for 
Compound Dataset within hOAT2 
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Compounds docked within hOAT3 include (A) acyclovir, (B) α-KG, (C) 
fluorescein, (D) PAH, (E) penicillin G, (F) probenecid, and (G) 
salicylate. Docked compound shown as space filling molecule within 
binding pocket, with potential amino acid contacts shown as line 
molecules. ES is absent since it has been docked previously ( and 
Figure 3.7 A & B). Image files generated using PyMOL 1.8. 
 Figure 4.6 Top Docking Solutions for Compound Dataset within hOAT3 
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 Using PyMOL v1.8, further analysis was focused within the suggested binding 
pocket to determine which amino acid contacts within the transporter are likely to be 
critical to compound recognition. Amino acids with potential compound interactions were 
identified, and the nature of the proposed interactions are summarized (Tables 4.2 – 4.4). 
Amino acid residues predicted to interact with the respective transporter are indicated by 
a check mark. Amino acid residues interacting with three or more compounds are 
highlighted yellow. Published compounds known to interact with hOAT1 (blue) and 
hOAT3 (red) are shown in Tables 4.2 and 4.4. Docking of the eight compounds in the 
hOAT1 model identified thirteen unique contacts across the dataset. Four of the five 
amino acids identified for PAH, Arg15, Ile19, Tyr230, and Arg466, interact with two or 
more other compounds, possibly indicating the importance of these residues in hOAT1 
compound recognition. In particular, Arg15 and Arg466 were identified for all examined 
compounds that interact with hOAT1 (blue, Table 4.2). Eleven out of the twelve unique 
residues identified within hOAT2 interacted with three or more compounds. Leu26 was 
found to interact with every compound listed, thus this position could be highly important 
in hOAT2 compound recognition (Table 4.3). For hOAT3, fifteen unique contacts were 
identified. Three of the five potential amino acid contacts identified with ES, Tyr342, 
Phe430 and Arg454, also interact with two additional compounds, emphasizing the 
importance of these residues in hOAT3 compound recognition. Within the compounds 
known to interact with hOAT3 (red), Tyr342 was identified as a critical contact for both 
probenecid and ES, while Arg454 was identified as a critical contact for both ES and α-
KG. ES and penicillin G did not share any similar binding contacts, which could be 
explained by the differences in structure; ES has a bulky tetracyclic ring and a sulfate 
119 
 
functional group while penicillin G has smaller, dispersed rings in addition to a carboxyl 




Table 4.2 Summary of hOAT1 GOLD docking studies 
hOAT1 Docking Studies 
Residue TMD PAH ES α-KG Probenecid Acyclovir Salicylate Penicillin G Fluorescein 
Arg15 1          
Ile19 1           
Thr22 1           
Leu23 1           
Val145 2           
Leu199 4            
Ser203 4           
Tyr230 5          
Leu434 10          
Asn439 10               
Ser462 11          
Arg466 11         
Ser469 11         
 
Compounds docked within in silico hOAT1 model. Check mark indicates potential amino acid contact. Yellow highlight 






Table 4.3 Summary of hOAT2 GOLD docking studies 
hOAT2 Docking Studies 
Residue TMD PAH ES α-KG Probenecid Acyclovir Salicylate Penicillin G Fluorescein 
Leu26 1         
Val29 1          
Leu30 1           
Val155 2           
Leu209 4           
Thr213 4           
Ser237 5           
Trp354 7          
Asn358 7           
Tyr362 7          
Tyr450 10         
Arg474 11          
 
Compounds docked within in silico hOAT2 model. Check mark indicates potential amino acid contact. Yellow highlight 
indicates amino acid interacts with three or more compounds.  
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Table 4.4 Summary of hOAT3 GOLD docking studies 
hOAT3 Docking Studies 
Residue TMD PAH ES α-KG Probenecid Acyclovir Salicylate Penicillin G Fluorescein 
His15 1                
Ile133 2              
Ile187 4              
Thr191 4          
Leu192 4           
Val195 4           
Tyr218 5            
Trp334 7              
Tyr342 7             
Leu422 10            
Phe426 10              
Ser427 10             
Phe430 10             
Leu431 10             
Arg454 11            
 
Compounds docked within in silico hOAT3 model. Check mark indicates potential amino acid contact. Yellow highlight 







Due to the limitations of technology in the past, visual representation of a protein’s 
structure was constrained to a two-dimensional view. With the first discovery of OATs in 
rodent and human [3,43], gene sequences were represented as either individual 
nucleotides or amino acids. To predict how the protein spanned the phospholipid bilayer, 
membrane topology predictions were performed using Kyte-Doolittle hydropathy analysis, 
a graphical representation which plots the hydrophilicity and hydrophobicity of individual 
amino acids which together makeup a protein [44]. While such analysis was adequate at 
the time, there has been increased use and development of technology in the 21st century. 
New and innovative methods are using computer-based systems to drive pharmaceutical 
based research. Among these advancements, homology modeling techniques have 
emerged based on the ability to generate three-dimensional in silico homology models 
for unresolved proteins, and thus was explored for OATs. 
hOAT1-3 homology models were generated, followed by the docking of multiple 
structurally diverse compounds. There have been numerous publications regarding 
compounds which interact with OATs, including antiviral agents, such as acyclovir [45–
47], β-lactam antibiotics, such as penicillin [47,48], non-steroidal anti-inflammatory drugs, 
such as salicylate [28,34,49,50], a uricosuric agent and OAT inhibitor, probenecid 
[28,47,51], the counter ion used to drive anion exchange via OATs, α-KG [42,52], the 
fluorescent moiety, fluorescein [28,42], as well as PAH [27,28,34,42] and ES [53–55], the 
prototypical substrates for hOAT1 and hOAT3, respectively. The ionized form of each 
compound was sketched and energy minimized in SYBYL-X v2.1 (Figure 4.1) then 
separately docked into each model. A top compound-transporter solution was determined 
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for hOAT1 (Figure 4.4), hOAT2 (Figure 4.5), and hOAT3 (Figure 4.6). Each compound 
was colored as such: acyclovir (yellow), α-KG (grey), ES (pink), fluorescein (green), PAH 
(orange), penicillin G (red), probenecid (purple), and salicylate (blue). hOAT1-PAH and 
hOAT3-ES homology models are absent from Figure 4.4 and Figure 4.6 due to extensive 
modeling studies previously performed (Chapter 2 and Chapter 3).  
Amino acid contacts for each compound were identified and reported (Table 4.2 – 
4.4). Amino acid contacts for hOAT1 were identified in TMDs 1, 2, 4, 5, 10 and 11, with 
three or more residues identified in TMDs 1 and 11 (Table 4.2), suggesting these TMD 
regions are highly involved in hOAT1 compound recognition. Four of the five residues 
identified for PAH, Arg15, Ile19, Tyr230 and Arg466, were identified with two or more 
compounds, suggesting the importance of these positions in hOAT1-PAH recognition and 
continued testing of these positions through in vitro efforts. Tyr230, a residue identified in 
a previous hOAT1 modeling publication [1], was identified for three known hOAT1 
compounds, PAH, probenecid and acyclovir, suggesting the importance of tyrosine’s 
benzene ring, which possesses the ability to form edge-face aromatic interactions, for 
hOAT1 compound recognition. Additionally, Arg15 and Arg466 were identified for all 
known hOAT1 compounds docked, suggesting a guanidinium group within these 
positions is very important in hOAT1 compound recognition. Residue Asn439 was 
identified to interact with only two compounds, PAH and ES, suggesting further analysis 
at this position be deprioritized. However, hOAT1 Asn439Gln and Asn439Ala mutants 
were identified as PAH transport inactive (Figure 2.12). Additionally, the interaction 
between Asn439 and PAH was a hydrogen bond, a strong intermolecular force. Future 
work requires docking of additional compounds to validate Asn439 as a critical contact. 
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Residues Thr22, Leu199, Ser203 and Ser462 were identified after docking penicillin G 
and fluorescein, but were not identified with PAH. This suggests structurally divergent 
OAT substrates may utilize different contact points to achieve membrane translocation 
via the transporter. Amino acid contacts for hOAT2 were identified in TMDs 1, 2, 4, 5, 7, 
10, and 11, with three or more residues identified in TMDs 1 and 7 (Table 4.3), suggesting 
these TMD regions are highly involved in hOAT2 compound recognition. Eleven of the 
twelve residues were identified to interact with three or more compounds, suggesting that 
it is unclear which contacts are most important in hOAT2 compound recognition. While 
every docked compound in Table 4.3 has been reported to interact with hOAT2, there are 
no verified prototypical substrates for hOAT2, or much transport data at all regarding 
hOAT2, including kinetic parameters, thus making it difficult to provide informed hOAT2 
docking conclusions. However, LEU26 stands out in that it was identified for all eight 
dataset compounds, the only position to do so. Human OAT2 also has the greatest 
number of suggested contacts for probenecid amongst these three paralogs. Once a 
prototypical hOAT2 substrate is determined, more informed suggestions and continued 
validation through in vitro efforts can be performed. Amino acid contacts for hOAT3 were 
identified in TMDs 1, 2, 4, 5, 7, 10, and 11, with three or more residues identified in TMDs 
4 and 10 (Table 4.3). Three of the five residues identified for ES, Tyr342, Phe430 and 
Arg454, were identified with two or more other compounds, suggesting the importance of 
these positions in hOAT3 ES recognition and continued testing of these positions through 
in vitro efforts. Two residues, Phe426 and Leu431, were only identified in ES docking 
studies, possibly indicating unique contact profiles for various substrate structures and 
again suggesting OATs are able to interface with such a broad array of structurally diverse 
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compounds by providing flexibility in contacts along its ‘translocation pathway’. These 
positions, along with Phe430, are important in forming hydrophobic interactions. 
Additionally, Tyr 342 and Arg454 were identified across two known hOAT3 compounds: 
ES and probenecid (Tyr342) & ES and α-KG (Arg454), suggesting the benzene ring 
(tyrosine) and the guanidinium group (arginine) are important for hOAT3 compound 
recognition. No common contacts were identified between ES and penicillin G, potentially 
due to the difference in compound structure: ES contains a bulky tetracyclic ring and a 
sulfate functional group while penicillin G has two dispersed rings and a carboxyl 
functional group. Position Tyr218 was identified to interact with three out of four known 
hOAT3 compounds, α-KG, probenecid, and penicillin G, but not identified to interact with 
ES. α-KG, probenecid, and penicillin G all possess a carboxy functional group, which is 
absent in ES. Therefore, Tyr218 may influence compound recognition if the compound 
possesses a carboxyl functional group.  
A similar number of contacts were identified upon hOAT1 (five), hOAT2 (four), and 
hOAT3 (four) PAH docking studies. Since PAH is the prototypical substrate for hOAT1 
(Km ~ 8.9 – 14.5 µM, [27,28]) and a weak substrate for hOAT2 (Km ~ NA, [42]) and hOAT3 
(Km ~ 87.2 µM, [34]), amino acid interactions were evaluated to identify correlations. Of 
the five hOAT1-PAH contacts identified, hydrogen bonding (Arg15, Asn439 and Arg466), 
hydrophobic (Ile19), and edge-face aromatic (Tyr230) interactions were identified. Similar 
interactions were identified for hOAT2 and hOAT3: hydrogen bonding (hOAT2: Arg474; 
hOAT3: Trp334), hydrophobic (hOAT2: Leu26 and Val29), and edge-face aromatic 
(hOAT2: Tyr450; hOAT3: Tyr218, Tyr342 and Phe430) Due to these similarities, it is 
unclear as to why such marked differences in PAH affinity exist across the three paralogs. 
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A similar number of contacts were identified upon hOAT1 (five), hOAT2 (four), and hOAT3 
(five) ES docking studies. Since ES is the prototypical substrate for hOAT3 (Km ~ 6 µM, 
[54]) and a weak substrate for hOAT1 (Km ~ NA, [53]) and hOAT2 (Km ~ NA, [55]), 
individual amino acid interactions were evaluated to potentially explain these differences 
in affinity. hOAT3-ES interactions include edge facing pi-system (Tyr342), hydrophobic 
(Phe426, Phe430, and Leu431) and hydrogen bonding (Arg454). As for hOAT1 and 
hOAT2, similar interactions were identified: edge-face aromatic (hOAT1: Tyr230; hOAT2: 
Tyr450), hydrophobic (hOAT1: Leu434 and Asn439; hOAT2: Leu26, Val29 and Leu30), 
and hydrogen bonding (hOAT1: Ser203 and Arg466). Once again, it is unclear as to why 
differences in ES affinity exist across paralogs. A similar comparison was conducted by 
assessing α-KG docking results. hOAT2 (five) had more contacts recognized as 
compared to hOAT1 (three) and hOAT3 (three). Although used as the counter ion to drive 
anion exchange on OATs, α-KG has no reported kinetic parameters for hOAT1, 2, or 3. 
For hOAT2-α-KG, two instances of hydrogen bonding (Asn358 and Arg474), two 
instances of an edge-facing pi-system (Trp354 and Tyr362), and one instance of the 
hydrophobic effect (Leu26) were identified. For hOAT1-α-KG, two instances of hydrogen 
bonding (Arg15 and Arg466) and one instance of the hydrophobic (Ser469) were 
identified, with no instances of an edge-face aromatic interactions. As for hOAT3-α-KG, 
edge-facing pi system (Thr191 and Tyr218) and hydrogen bonding (Arg454) were 
identified, however there were no instances of extensive hydrophobic interactions. This 
suggests the importance of an additional edge-face aromatic and hydrogen bond 
interaction in α-KG recognition, however this is only speculative due to the lack of kinetic 
estimates and further mutational studies are required. Finally, probenecid has been used 
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as the prototypical inhibitor in OAT studies based on its strong inhibitory effect for hOAT1 
(Ki ~ 4 µM, [28]) and hOAT3 (Ki ~ 4 µM, [47]), and weaker inhibitory potential for hOAT2 
(Ki ~ 766 µM, [51]). Numerous contacts were identified in hOAT1 (eight), hOAT2 (nine), 
and hOAT3 (four) docking studies. Five hOAT1 contacts (Ile19, Thr22, Leu23, Val145, 
and Leu199) and six hOAT2 contacts (Leu26, Val29, Leu30, Val155, Leu209, and 
Ser237) were identified as contributing to hydrophobic interactions, suggesting the 
importance of this interaction in probenecid recognition. Three instances of edge-face 
aromatic were identified in hOAT3 (Tyr218, Trp334, and Tyr342), suggesting the cyclic 
features within these residues aid with hOAT3-probenecid recognition. Based on the 
sheer number and strength of contacts identified, it is not surprising that probenecid is a 
strong OAT inhibitor. 
In summary, novel in silico homology models for hOAT1-3 based on the solved 
structure of PiPT were successfully constructed and validated. Numerous structurally 
diverse compounds which have been published to interact with OATs were docked within 
the generated models. Amino acid contacts were primarily found in TMDs 1, 2, 4, 5, 10, 
and 11, suggesting that these TMDs are important in compound recognition. Four of the 
five residues identified in hOAT1-PAH docking studies interacted with two or more 
compounds, indicating the importance of these residues in hOAT1 substrate recognition. 
For hOAT2, eleven of the twelve amino acid contacts identified interacted with three of 
more compounds, suggesting initial positions to investigate for continued hOAT2 
substrate recognition studies. Three of the five residues identified in hOAT3-ES docking 
studies interacted with two or more compounds, indicating the importance of these 
residues in hOAT3 substrate recognition. Similar residue counts and residue interactions 
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were identified after PAH, ES and α-KG docking studies across paralogs. Numerous, 
strong interactions were identified after probenecid docking studies, validating that 
probenecid is indeed a strong OAT inhibitor. These preliminary docking studies provide 
an initial starting point for continued analysis using these hOAT1-3 homology models. 
Future work involves docking the library of FDA compounds to further develop, validate, 




CHAPTER 5 – FUTURE APPLICATION 
 
 
There has been a recent surge in additional techniques to further characterize 
compound interactions with SLC transporters, specifically through utilizing homology 
modeling supplemented with in vitro validation. Having the ability to assess whether a 
compound could interact with an ADME-relevant transporter, specifically through use of 
an in silico model, could expedite the early stages of drug discovery, in addition to 
potentially uncovering further information regarding ligand-transporter interactions [25]. 
Therefore, using these in silico models could be beneficial to 1) screen the FDA library of 
drug molecules to predict interacting drugs, 2) screen a large compound dataset to predict 
novel interacting molecules in silico followed by testing in vitro to identify new leads, or 3) 
potentially uncover key structural components as a means of informed rational drug 
design. 
The generated models can be used for further assessment of key amino acid 
contacts and binding regions via docking of additional compounds. Docking the dataset 
of FDA compounds, for example, then comparing the strength of each drug’s interaction 
with the OATs could elucidate common themes defining ligand-OAT interactions, e.g., 
which structural features specifically interact with OATs. Identifying compounds with 
similar structural characteristics could result in identification of novel interacting drugs, 
perhaps even aid in predicting potential clinical drug-drug interactions. 
 Additional screening of a large commercial compound dataset could be used to 
predict novel molecules for continued testing in vitro as potential lead compounds for 
further development that specifically target OATs. For some molecules, this could provide 
a viable elimination pathway for the potential lead, which in turn benefits the compounds’ 
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safety profile by diminishing the potential for drug toxicity due to prolonged exposure. 
Alternatively, designing a potential OAT inhibitor to block elimination could also be 
pursued, especially if prolonging the drug’s exposure in systemic circulation is necessary 
to reach efficacious drug concentration levels for a therapeutic effect. 
Additional rational drug design strategies could be implemented as a result of 
continued modeling. Using known OAT substrates or inhibitors, there is potential to 
identify therapeutic vs OAT-interacting regions of the molecules which can then be 
exploited to design a more efficacious drug. Through the synthesis of a series of 
compounds with targeted modifications of specific functional groups, these various 
physiochemical features controlling each aspect can be probed by evaluating differences 
in accumulation levels and transport affinity. By identifying the separate therapeutic and 
OAT-interacting regions of a compound, there may be the potential to reduce renal 
elimination, increase half-life and decrease a patient dose or dose frequency, thus leading 
to increased patient compliance and benefit, in turn leading to safer and more cost-
effective drug designs.    
The current study is paving the way toward an innovative method to gather new 
information involving the binding complex location, and molecular level interactions, to 
aid in assessing the underlying mechanism of transport for hOAT1-3. Initial investigation 
of identified residues of the prototypical substrates for hOAT1 (PAH) and hOAT3 (ES) 
may offer insight to transporter-substrate recognition within each respective transporter 
in addition to other SLC22 family members. These preliminary studies offer a method for 
continued assessment of and screening for potential substrates/inhibitor, increasing our 
132 
 
ability to predict and avoid clinical drug-drug interactions, which in turn can lead to safer 
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